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Dengue is an acute febrile illness caused by an enveloped positive-stranded 
RNA virus. Dengue disease manifests in a wide range of clinical symptoms 
and is usually accompanied by hematological changes such as leukopenia and 
thrombocytopenia. Complications of infection such as severe plasma leakage 
leading to shock, severe bleeding or severe organ impairment (such as liver 
damage as indicated by increased liver transaminases in the circulation) 
mostly occur at the time of fever defervescence.  A major road block in the 
study of dengue infection and development of therapeutics for dengue is the 
lack of a robust small animal model.  
An immune-deficient mouse with a long term stable reconstitution of human 
immune cells is a robust and conducive system to study various infectious 
diseases that do not have an efficient animal model, like dengue. Adoptive 
transfer of fetal liver CD34
+
 cells into NOD-scid Il2rg
-/-
 mice give rise to 
significant levels of human platelets, blood lineage cells such as 
monocytes/macrophages (that are believed to be the targets of dengue) and 
hepatocytes in the mouse liver. These features make it possible to study 
dengue infection and its pathogenesis in a human cell context in the 
humanized mouse. 
I have successfully established dengue infection in the humanized mouse by 
infecting them intravenously with a dengue serotype-2 virus, which required 
human cells for replication. Systemic infection was observed in the mice, with 
infective viral particles found in the serum (peaking at day 7 post-infection 
and detectable up to a month), liver, lymphnode, spleen and bone marrow. 
Clinical features such as thrombocytopenia, specifically of human platelets 
ix 
 
(with no change in mouse platelets), transient leukopenia of human immune 
cells in the blood and increase in liver transaminases were also seen in the 
infected mice, as seen in dengue infected patients. I have used this model, to 
investigate the mechanism underlying the depletion of human platelets, giving 
an insight into dengue-induced thrombocytopenia in humans. I show that 
induction of thrombocytopenia is associated with depletion of platelet 
progenitors, the human megakaryocytes and the human megakaryocyte 
progenitors, megakaryocytic colony forming units in the bone marrow. As no 
dengue-specific human antibodies were detected in humanized mice, the 
depletion of platelets in the periphery is unlikely to be a significant factor.  
Instead, it was shown that inhibition of megakaryocyte development in the 
bone marrow and therefore suppression of platelet production is the primary 
cause of thrombocytopenia in this model. In addition I have also used this 
model to study a single nucleotide mutation in the 3`untranslated region which 
resulted in variations in the replicating efficiencies of the virus. It caused 
alterations in the stability and replication ability of the virus and enabled the 
virus to infect the mouse cells in the NOD-scid Il2rg
-/-
 mice.  
In summary, I have established a humanized mouse model of dengue infection 
that recaptures some of the clinical symptoms seen in humans. The improved 
humanized mouse model of dengue infection could help in the investigation of 
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1.1 DENGUE INFECTION 
Dengue disease is an acute febrile illness caused by a small, enveloped single 
stranded RNA virus (belonging to the family flaviviridae). It is the fastest 
spreading arthropod borne disease that is spread through the mosquito vectors 
Aedes egyptii, A. Albopictus and A. polynesiensis (Simmons et al. 2012). 
There are four serotypes of this virus (Dengue 1,2,3,4) which are grouped 
according to their antigenic property (Halstead 2007).  DENV is distributed 
worldwide in tropical and subtropical regions with nearly 2.5 billion people 
living in endemic regions (Gubler 2002;Tolle 2009;Tatem et al. 2006). 
Recently, there has been a 30 fold increase in dengue infections, with new 
occurrences in non-endemic countries and rural regions (Figure 1.1, 1.2) 
(WHO 2009). In a recent study (Bhatt et al. 2013), it has been reported that the 
total number of infections every year is about 390 million and at least three 
times the dengue burden estimated by the World Health Organization (WHO 
2009).  
 
Figure 1.1 Distribution of dengue endemic areas according to the WHO (2009). 




Figure 1.2 Average number of dengue fever and dengue hemarrhagic fever 
cases reported from 1955 – 2007 by WHO (2009). The red line shows the number 
of countries where dengue cases have been reported in each decade. The bars are the 
average number of dengue cases reported world wide in each decade. 
1.1.1 Disease symptoms and classification 
Dengue disease manifests itself with varying degrees of severity, often with 
unpredictable outcomes. Most of the patients have a self-limiting, non-severe 
flu-like infection from which they rapidly recover. However, a small 
proportion of them develop severe symptoms such as shock and hemorrhage, 
which can be fatal when left untreated.  
The World Health Organization (WHO) had initially tried to classify dengue 
based on its different levels of severity; asymptomatic dengue infection and 
symptomatic dengue infection. The latter was further classified into three 
categories: undifferentiated fever, dengue fever (DF) and dengue hemorrhagic 
fever (DHF). DHF was then classified into four grades based on the number of 
hemorrhagic presentations, with grade III and IV classified as dengue shock 
syndrome (DSS) (Figure 1.3A) (WHO 1997). Despite the classification being 
widely used, epidemiological changes of dengue along with increasing 
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incidences of severe cases that failed to fulfill the criteria for DHF or DSS 
made the application of this classification challenging in a clinical set-up.  
In the new WHO classification, dengue infection was classified as non-severe 
(with or without warning signs) and severe dengue (Figure 1.3B). When fever 
is accompanied by any two of the following symptoms – nausea, vomiting, 
rash, pain, positive tourniquet test or leukopenia, it is classified as non-severe 
dengue without warning signs. When symptoms or warning signs such as 
persistent vomiting, abdominal pain, restlessness, mucosal bleeding, liver 
enlargement and/or increase in hematocrit values (HCT) are present along 
with a drop in platelet counts (thrombocytopenia), it is classified as non-severe 
dengue with warning signs. Such patients usually improve after defervescence. 
In severe dengue, patients with or even without warning signs develop further 
complications such as severe plasma leakage leading to shock, severe bleeding 
or severe organ impairment (for the liver it is measured by increase in liver 
transaminases; alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST)), impaired consciousness and/or failure of heart and other organs 
(WHO 2009). The disease needs to be carefully assessed and managed during 
all the three phases – febrile, critical and recovery phase (Figure 1.4) (WHO 
2009). When acute fever sets in abruptly with or without some of the warning 
signs, the patient is said to be in febrile phase which lasts about 2-7 days. 
After this phase when the fever subsides, a sudden increase in HCT values 
indicates that the patient is entering the critical phase. If the patient survives 
the 24-48 hour critical phase, recovery occurs in the next 48-72 hours with 
stabilization of all clinical parameters. However, some patients might progress 
to severe dengue with severe bleeding, plasma leakage and organ impairment 
after the critical phase.  
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Primary infection with one strain usually causes life time immunity against 
that same serotype of the virus after recovery (Sabin 1952). However, 
subsequent secondary infections with another serotype of the virus increases 
the chances of developing DHF or DSS in the patients by 40-80 times 
(Halstead 2003). It is also reported that around 90% of DHF or DSS occur in 




Figure 1.3 Dengue disease classifications according to  (A) WHO (1997)  





Figure 1.4 Different phases of dengue infection according to WHO (2009). The 
different phases of dengue disease include the febrile phase, critical phase and 
recovery phase where the severe symptoms of DHS or DSS fall in the critical phase. 
1.1.2 Transmission and course of the disease 
When a female Aedes mosquito feeds on the blood of a dengue infected person 
it acquires the virus which infects the mosquito’s midgut epithelium and 
actively replicates in it. Subsequently, the virus reaches the hemocoel through 
which it gains access to other organs, mainly the salivary gland (Salazar et al. 
2007). Once the salivary gland is infected, the virus can infect the next human 
the mosquito feeds on through the saliva. This period is called the extrinsic 
incubation period and takes approximately 10-14 days post the first blood 
meal (Figure 1.5). Once infected, a mosquito, remains infected its entire life 




Once a human is bitten by an infected mosquito, there is an intrinsic 
incubation period of 3-14 days when the virus actively replicates in its target 
cells. When the viremia reaches its maximum in the blood, the patient enters 
the febrile stage of the disease (Gubler 1998). After 5-7 days of onset of fever, 
the viremia starts to drop and the warning signs start to appear. DHF or DSS 
usually develop during this defervescence phase, which can cause death when 
left untreated for 12 to 24 hours. After defervescence, the dengue (serotype) 
specific IgM can be detected in the serum for about 6 months and IgG can be 
detected throughout their life (Figure 1.6). 
 
Figure 1.5 Transmission of the DENV from human-mosquito-human. The 
mosquito first feeds on the infected human and there is an extrinsic incubation period 
where the virus replicates in the mosquito. When the mosquito bites another human, 






Figure 1.6 Course of dengue disease in humans. After the incubation period, there 
is a peak in viremia where the fever sets in. The severe symptoms are observed 
during the defervescence stage. Dengue specific antibodies develop during the 
recovery phase which gives the person life-long immunity against that specific 
serotype 
1.1.3 Pathogenesis of disease 
Sequence of events during dengue infection 
 According to the most accepted theory of how the DENV enters the 
circulation of blood (Martina et al. 2009), when an infected mosquito bites the 
skin of a person, the virus is injected into the blood stream with a little spill 
over  in the epidermis and dermis, where it infects the local immature skin 
Langerhans cells (Limon-Flores et al. 2005;Wu et al. 2000;Wu et al. 1995). 
From here, the infected cells migrate to the draining lymph nodes (LN), where 
recruited monocytes and macrophages are infected. Similarly, the virus infects 
the resident tissue macrophages in several organs through the circulating blood 
stream, especially the liver and spleen (Balsitis et al. 2009;Basílio-de-Oliveira 
et al. 2005). This results in amplification and dissemination of virus through 
the lymphatics and blood circulatory system. At this point, the blood derived 
monocytes; myeloid dendritic cells (DC) and other tissue macrophages 
become infected which in turn increases the viral load in the blood. This entire 
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process can take up to 2 weeks before viremia peaks and the viremia can be 
detected in the serum.  
Severe dengue disease 
When a person gets infected with one serotype of DENV (primary infection), 
there is life-long immunity against that serotype. However, infection with a 
second serotype of DENV (secondary infection) can occasionally result in 
disease severity and complications. Severe dengue disease occurs 4-5 days 
post onset of symptoms when the viremia has reduced to low levels through 
host clearance mechanisms (Duyen et al. 2011), suggesting there may be a link 
between host response and severity of the disease (Green et al. 1999;Libraty et 
al. 2002). Plasma leakage, which is one of the severe manifestations, is 
thought to occur because of micro vascular dysfunction due to exposure to 
inflammatory mediators on the endothelial wall (Basu and Chaturvedi 2008). 
One proposed mechanism is the transient disruption of the surface glycocalyx, 
a matrix of proteoglycans and glycosaminoglycans lining the vascular 
endothelium that regulates microvascular filtration, due to inflammation on the 
endothelial wall (Wills et al. 2004;Michel and Curry 1999). Severe organ 
damage can also occur as a result of cytolysis or inflammation induced by the 
massive immune response. Hence, it is believed that the host response to the 
virus and not the virus itself causes the disease symptoms and the 
complications that follow. 
 Though several hypotheses are proposed, the exact mechanisms behind severe 
manifestations are not known conclusively.  Many evidences point to a high 
correlation between an increased viral load and disease severity (Vaughn et al. 
2000;Libraty et al. 2002;Rothman 2004;Martina et al. 2009), {though a study 
10 
 
recently has contradicted this view (Libraty et al. 2009) }, where the high viral 
load, specifically during secondary infections, is caused by antibody 
dependent enhancement (ADE) or massive activation of cross reactive T cells 
due to original antigenic sin, leading to cytokine storm and severe disease 
manifestations. These mechanisms are explained briefly in the following 
sections. 
Antibody dependent enhancement 
Observations that secondary infections in infants (6 to 9 months) are usually of 
the severe form when they get infected with a serotype that is different to the 
one which had infected their mothers, particularly when the mothers have sub-
neutralizing antibodies of the first serotype  lead to the idea of the 
phenomenon called antibody dependent enhancement (ADE) (Halstead 
1970;Kliks et al. 1988). This occurs when the antibodies developed during the 
primary infection against the first virus fail to neutralise the virus from the 
secondary infection. These sub-neutralising antibodies form complexes with 
the virus and attach to the Fc receptors I and II (Kontny et al. 1988;Littaua et 
al. 1990) on the target cells such as mononuclear phagocytes. The virus then 
uses these receptors to infect and replicate in the target cells (Halstead and 
O'Rourke 1977). The hypothesis of ADE is further divided into two proposed 
mechanisms – the “extrinsic” ADE where the high viral load is due to an 
increased number of infected FcγR positive cells and an “intrinsic” ADE 
where there is suppression of cellular innate immunity (by disabling type I 
IFN pathways through negative regulators and high production of IL-10, 
inactivating the JAK-STAT pathway) leading to more virus replication 
(Halstead 2003;Ubol et al. 2010).  
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i. Cross reactive T cell activation 
In secondary heterologous infections, pre-existing cross reactive memory T 
cells, which were sensitized earlier from a previous infection and have low 
avidity to these antigens, compete with naïve T cells which have high avidity 
for the antigens to recognize the antigens.  These results in proliferation and 
activation of the low avidity cross reactive CD8
+
 T cells with no cytolytic 
activity, leading to failure to clear infected cells (Mangada et al. 
2002;Rothman 2004). This results in the production of high levels of IL-6, 
TNF- and other soluble factors which directly act upon vascular endothelial 
cells resulting in plasma leakage (Martina et al. 2009). This correlated with the 
observation that T cell activation is greater in severe patients than in patients 
with mild dengue (Pang et al. 2007) (Pang et al. 2007). 
ii. Cytokine storm 
Due to the tremendous activation of T cells, a cytokine cascade is triggered 
which mainly targets the vascular endothelial cells, resulting in fluid and 
protein leakage (Martina et al. 2009). Cytokines such as IFN-, TNF-, IL-1, 
IL-2, IL-6, IL-8 etc. increase and are usually seen elevated in patients with 
severe dengue (Basu and Chaturvedi 2008;Hober et al. 1996;Bethell et al. 
1998). These cytokines can also act together and also induce the release of 
certain other cytokines and chemical mediators thus creating abnormal levels 
of cytokine production called ‘cytokine storm’, resulting in plasma leakage 
and organ failure (Bozza et al. 2008). However, since cytokine storm is also 
seen in conditions such as sepsis (Ye et al. 2012;Otto et al. 2013), where there 
is no vascular leakage, other dengue-specific mechanisms may be contributing 
to the plasma leakage that is commonly seen in severe dengue patients 
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The cascade of ADE-viral replication-T cell activation-cytokine release may 
not be strictly in the linear sequence but probably a complex interplay, acting 
synergistically and ultimately resulting in plasma leakage, circulatory failure 
and shock (Pang et al. 2007). However, further research is required to dissect 
the actual mechanisms and pathways involved in manifestation of severe 
dengue disease. 
1.1.4 Disease diagnosis 
As discussed earlier, dengue disease manifests itself in a wide spectrum of 
clinical symptoms. Doctors measure platelet drop in the blood of patients to 
rapidly confirm dengue infection as it is a unique predictive marker for DENV 
infection (Pang et al. 2007). However, diagnosis of the disease based solely on 
the clinical symptoms might be misleading or not reliable as it might lead to 
fatality due to misinterpretation of symptoms (as many symptoms are not 
specific) or might lead to over-hospitalization (a public health cost issue, 
especially in resource poor countries), thus underscoring the importance of 
laboratory diagnosis along with correct assessment of clinical symptoms. At 
present, the diagnosis in laboratories is done through one or in combination of 
the following three methods: isolating and characterizing the virus from the 
serum of the patients by cell culture, amplifying the viral sequence from the 
viral particles isolated from the serum or blood of patients by molecular 
biology methods such as RT-PCR or serological analysis by detecting dengue 
specific antigen or antibody in the patients (Lee et al. 2012). 
During acute phase infections, when patients are viremic, dengue infection is 
confirmed through detection of the virus or viral particles in the patient. Virus 
isolation by cell culture using mosquito cell lines C6/36 (most preferred)  AP-
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61, AP-64 etc. or mammalian cell lines such as BHK21 and its 
characterization by plaque assay or immune-fluorescence is accepted as the 
most reliable or the ‘gold standard’ diagnostic procedure. However, due to its 
lower sensitivity and longer detection time other methods are now preferred. 
At present there is a wide range of published protocols for the molecular based 
diagnostic tests using the principle of PCR for detecting DENV in the blood 
(serum or plasma) (Shu and Huang 2004) (Harris et al. 1998) (Henchal et al. 
1991) (Lanciotti et al. 1992). The main advantage of these tests is the 
detection of all of the four serotypes separately or simultaneously in the same 
sample. However the disadvantage in these tests is that both the viral isolation 
techniques and molecular biology methods can only diagnose acute (on-going) 
or recent dengue infection when the serum samples are tested within 5 days of 
the onset of symptoms.  
In the absence of acute phase samples, or for further confirmation of infection, 
serological based tests such as detecting the viral antigen or the virus specific 
antibodies are routinely used. IgM or IgG antibodies primarily to the viral E 
protein are detected in the serum of the patients through the IgM antibody 
capture enzyme linked immunosorbent assay (MAC-ELISA) or IgG ELISA 
(Morita et al. 1991;Martin et al. 2000). The advantage of the serological tests 
is diagnosis of primary and secondary infections. Confirmation of primary 
infection is done in paired samples (acute and convalescent phase) when there 
is negative to positive seroconversion of IgM or IgG antibody to viral 
antigens. During secondary infections, the IgG antibody is positive in the 
acute phase and there is a four-fold increase in their titres in the convalescent 
phase. The IgM antibodies can be detected from 5 days until 90 days post 
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onset of symptoms, which is also useful in detecting patients with recent 
probable DENV infections. However, a major disadvantage in these tests is 
that though the sensitivity is very high, the specificity is relatively lower due 
to the cross reactivity of the antibodies within all serotypes of DENV and also 
with other Flaviviruses (Blacksell et al. 2012). The NS1 protein detection has 
been suggested as a potential diagnostic test for early DENV infection 
(Blacksell et al. 2011;Alcon et al. 2002). The antigen can be detected in the 
serum as early as 1 day until 18 days post onset of symptoms. The specificity 
of this assay is extremely high as it can even differentiate between different 
flavivirus infections. A limitation to this test is that the sensitivity rapidly 
decreases over time as the levels of the circulating NS1 depend on the 
infecting serotype, immunological status (primary or secondary infection) and 
disease severity (Koraka et al. 2003). Combination of both the antigen and 
antibody dependent tests have shown to improve both the sensitivity and 
specificity of detecting a DENV infection (de la Cruz-Hernández et al. 2013). 
Recently both saliva and serum from patients have also been used to detect 
DENV specific IgA or IgM during the early phase of infection (Blacksell et al. 
2011;Balmaseda et al. 2003). 
Even though through these tests the presence of DENV infection can be 
confirmed, at present there are no predictive biomarkers to predict which 
patients might develop severe disease and which patients can recover with 
mild symptoms. This factor is very important during epidemics to identify 
patients who might need hospitalization and medical care. There have been 
many reports of predictive markers for severity such as MIP-, IFN-, IP-10 
etc (Yap et al. 2011;Kumar et al. 2012);(Bozza et al. 2008;Brasier et al. 2012), 
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however they may not be reliable as none of these markers are specific to 
dengue or sensitive enough to predict disease severity.. The combination of all 
these diagnostic tests along with the predictive markers can help in the 
management and treatment of DENV infected patients. 
Management and treatment of infection  
At present, there are no specific drugs to treat dengue disease. Proper medical 
care and triage during the primary and secondary care levels (when the patient 
first seeks medical attention) is not only very important in saving the life of 
the patient but also in avoiding over-hospitalization. Management of infection 
includes medications (excluding NSAIDs) to control fever and body pain, 
proper administration of fluids, hospitalization, intravenous rehydration as 
well as careful monitoring of clinical parameters and warning signs (Kumar et 
al. 2012). In severe cases of shock, timely blood volume replacement can save 
the life of the patient. Two decades ago, the fatality due to DHF and DSS was 
reported to be around 41% (WHO 2009) when not much knowledge and 
awareness of this disease was available. Today, the fatality rate can be brought 
down to less than 1% in severe cases with proper treatment and management 
(Sumarmo 1987). 
 
1.1.5 Development of therapeutics and prevention 
There are some major challenges in developing therapeutics for dengue 
disease. Various therapeutics that are being evaluated are antivirals to inhibit 
DENV infection, immune-modulators to control the host response to the 
disease and vaccines to prevent DENV infection. But at present the most 




As there are evidences that suggests a correlation between viral load and 
disease severity in dengue, since the disease is hypothesized to be caused by 
the increased host immune response to an increased viral load (WHO 
2009;Vaughn et al. 2000), controlling the viral load at an early stage of the 
disease may help to reduce severity. Potential anti-viral compounds that are 
currently being investigated are candidates that inhibit: 
 the virus at the point of entry such as monoclonal antibody (14c10) (Libraty 
et al. 2002),  heparin (Teoh et al. 2012) and cinnamic acid derivatives 
(Hung et al. 1999) 
 viral RNA polymerase/methyltransferase such as Ribavirin (Rees et al. 
2008) or nucleoside analogs such as NITD008 (Benarroch et al. 2004) 
 nucleotide synthesis or replication such as mycophenolic acid (Yin et al. 
2009)and Chloroquine (though the latter failed in a clinical trial as it did not 
result in reduction in viremia in patients (Diamond et al. 2002) 
 -glucosidase I (which is important in viral protein folding and budding 
from cells) such as the naturally occurring alkaloid Castanospermine 
(Tricou et al. 2010) or its pro-drug Celaden (Celgosovir) (Whitby et al. 
2005).  
 protein kinases (that regulates NS5 activity and endocytosis of DENV, 
immune evasion and cell survival during infection) such as Dasatinib and 
AZD0530 (Watanabe et al. 2012) 
Some of these compounds are under clinical trials at present to test their 
efficacies as anti-virals and their ability to control disease progression and 
severity in patients. However a limitation of using anti-virals is that usually 
the patients approach medical care during the onset of severe symptoms, by 
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when the virus is cleared from the system. Nevertheless, with the emergence 
of rapid dengue detection methods and the spread of awareness of this disease, 
the use of anti-virals can help in the treatment of the disease. 
ii. Vaccines 
An ideal dengue vaccine is one that gives life time immunity by producing 
neutralizing antibodies against all the four serotypes of the virus at the same 
time. However, this is a major challenge as it is very difficult to obtain a 
balanced tetravalent response, the absence of which can lead to severe disease 
through a mechanism called antibody dependent enhancement (ADE) (which 
is discussed in detail later).  Research and development of vaccines has been 
under study for the past 50 years which has resulted in development of 
potential vaccine candidates such as live (attenuated, chimeric and live virus 
vector) and non-living (inactivated, recombinant subunit and naked DNA) in 
the last ten years.  
The first vaccine candidate to enter the phase 2b of clinical trials is Sanofi 
Pasteur’s ChimeriVax-Dengue tetravalent vaccine which underwent efficacy 
tests in Thailand (Chu and Yang 2007) (Sabchareon et al. 2012) (Guy et al. 
2010). Disappointingly, the efficacy of the vaccine was just 30% and it was 
not protective against DENV2, which was endemic during that time. 
Nevertheless, for the first time in the history of dengue, this clinical trial 
proved that a safe vaccine against dengue is possible. The vaccine is now 
undergoing phase 3 studies. A few other vaccine candidates are also in phase 1 





Table 1.1 List of few potential DENV vaccine candidates that have 
reached clinical trials (Adapted from (K. Senior 2009), (Coller and Clements 
2011)) 




ChimeriVax Sanofi Pasteur III 




























iii. Immune-modulatory drugs 
As described earlier in section 1.1.3, it is believed that there may be a link 
between host response and severity of the disease. The endothelial layer may 
be damaged due to a massive inflammatory response causing plasma leakage. 
Thus anti-inflammatory drugs may help to control or reduce the disease 
severity if administered early. The potential drugs that are being tested at 
present are corticosteroids (such as Prednisolone) and statins (such as 
Lovastatin). Prednisolone is a corticosteroid with a predominant 
glucocorticoid that can bind irreversibly to glucocorticoid receptors, helping to 
modulate the function of the endothelial glycocalyx and thus may prevent 
damage to the endothelium (Herrero et al. 2013). However, the use of 
Prednisolone to treat dengue disease is still under debate as it has been shown 
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to rescue patients with severe disease in some cases (Chappell et al. 2007), 
while it has failed to show significant effects in a recent clinical trial 
(Premaratna et al. 2011). Lovastatin belongs to the statin drug family, whose 
effects include restoration or improvement of endothelial cell function, an 
increased production of nitric oxide, and a reduction in the release of 
cytokines and acute phase proteins, thus leading to a reduction of 
inflammation within the vessel wall (Tam et al. 2012). Additionally, it has also 
been shown that may have an anti-viral effect on DENV replication (Ii and 
Losordo 2007). At present the effect of this drug during dengue disease is 
being evaluated in a clinical trial (Martínez-Gutierrez et al. 2011).  However, 
no one of these therapeutics are commercially available, putting the burden on 
vector control to prevent the spread of this disease at present. 
Prevention through vector control 
The current prevention of this disease mainly relies on the control of mosquito 
vectors that play an important role in transmission. The traditional methods of 
vector control are by environmental management (such as proper management 
of water resources and wastes, good sanitation and hygiene) or chemical 
control (such as spraying insecticides) (Whitehorn et al. 2012). But recently, 
modern vector control techniques like the use of genetically modified sterile 
mosquitoes (WHO 2009) or mosquitoes infected with a certain species of 
bacteria (which makes them resistant to dengue infection) (Wilke and Marrelli 
2012) are being explored to eliminate DENV transmitting mosquitoes. 
Nevertheless, creating a wide spread awareness of the disease and its 




1.2 DENGUE VIRUS (DENV) 
1.2.1 DENV morphology and genomic organization 
Member of the genus Flavivirus, DENV is a group of four closely related but 
having distinct antigenic property viruses known as serotypes. They are 
believed to have evolved from ancient sylvatic viruses around 1500 years ago 
(Lu et al. 2012).  Like all flaviviruses, they are transmitted by arthropod 
vectors (such as mosquitos) to vertebrate hosts (humans). Dengue virions are 
small and spherical with a diameter of 50nm and a smooth surface. They have 
a nucleocapsid with a single positively stranded RNA of 10.7 kb and are 
covered by a host derived lipid bilayer. The RNA replicates using a semi 
conservative method, which requires an intermediate double stranded 
replicative form of RNA that then forms nascent single strands (Wang et al. 
2000) (Kuhn et al. 2002).  
They have a single open reading frame (ORF) that is translated into a 
polyprotein which is cleaved post translation by viral and host proteases into 
three structural proteins (Capsid (C), membrane precursor (prM) and envelope 
(E) protein) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, 
NS4A, NS4B and NS5) (Zhang et al. 2003); Figure 1.7). The C protein along 
with the single stranded RNA forms the nucleocapsid. The prM is 
proteolytically cleaved by the host protease furin to form the membrane 
protein in mature virions and is embedded along with the E protein in the lipid 
bilayer (Perera and Kuhn 2008). The E protein is of primary interest for 
developing drugs or vaccines since it determines the host-cell tropism such as 
attachment to host cell receptors or fusion with cell membrane. It is also the 
main target of host neutralizing antibodies (Chambers et al. 1990;Roehrig et 
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al. 2004).  The non-structural proteins are mainly involved in viral replication 
(NS1, NS2A, NS4A), protease activity (NS2B, NS3), blocking host IFN α/β-
induced signal transduction (NS4B) and RNA polymerase activity (NS5) 
(Chambers et al. 1990). The ORF has two untranslated regions (UTR) one at 
5` end with about 100 nucleotides and the other is at 3`end with 500 
nucleotides. The 5` end has a type 1 cap but the 3` end lacks the polyA tail 
unlike the host mRNA. (Perera and Kuhn 2008). The 5` and the 3` end are 
believed to be involved in the initiation of negative strand synthesis as soon as 
the viral RNA is released into the cytoplasm, in initiation of translation, 
switching from negative strand synthesis to progeny plus strand synthesis and 
packing it into the viral particle (Chambers et al. 1990) .  
 
Figure 1.7 Genomic organization of DENV.  The viral genome has a cap at the 5` 
end, followed by the 5`UTR, 3 structural and 7 non-structural protein encoding ORF 
and a 3`UTR at the end. 
1.2.2 Primary targets and cellular receptors for DENV 
There have been reports of many targets and cellular receptors for DENV but 
the most widely accepted are the cells of the mononuclear/myeloid lineage 
like monocytes, macrophages and DC. The initial targets of DENV are the 
human skin dendritic cells, known as Langerhans cells (Markoff 2003) which 
are 10-fold more permissive than the blood monocytes or macrophages. The 
infection of the DCs occurs through the DC-specific intercellular adhesion 
molecule 3 grabbing non-integrin or DC-SIGN (CD209) (Wu et al. 2000).  
The receptor is highly expressed in immature DCs and facilitates the initial 
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infection of these cells. When the mature DCs do not possess high levels of 
DC-SIGN, their infection is facilitated by their Fc receptors, through ADE. 
The Fc receptors derive their name from their binding specificity for a part of 
an antibody known as Fc (Fragment, crystallisable) region. It is also reported 
that at least in the peripheral blood,  monocytes are the primary host cells for 
DENV replication (Tassaneetrithep et al. 2003). The surface antigen CD14, 
which is mainly expressed on the cells of the myeloid lineage (specifically, the 
monocytes) is also the putative receptor for DENV (Durbin et al. 2008). The 
infection of macrophages by DENV is mediated by the mannose receptor 
(CD206), a C type lectin domain family member (Chen et al. 1999). There are 
other cellular receptors that are used by the virus to infect the target cells 
including heparan sulfates (Miller et al. 2008) or CLEC5A (Chen et al. 1997).  
When the virus is in complex with specific antibodies, it uses Fc and 




1.3 ANIMAL MODELS OF DENGUE 
The major obstacle for the development of a drug or vaccine for dengue is the 
absence of a robust animal model to test the therapeutics. This is because wild 
type DENV can only infect humans. Intensive research for nearly a decade 
and manipulation of vial and host factors resulted in many animal models of 
dengue including non-human primates, immune-competent and immune-
compromised mouse models (Porterfield 1986). 
1.3.1 Non-human primate models (NHP) 
The common NHP models used are Rhesus (Macaca mulatta) and 
Cynomolgus (Macaca. fascicularis) monkeys. DENV was able to replicate in 
the lymphoid tissues when infected with 1x10
5
 pfu of the virus, sub-
cutaneously (s.c), though the viremia was much lower than that found in 
humans (Zompi and Harris 2012). Leukopenia and occasionally 
thrombocytopenia were seen in the infected monkeys, but there were no other 
clinical signs (Marchette et al. 1973;Halstead et al. 1973).   Nevertheless, the 
monkeys elicited a good antibody response similar to the levels seen in 
humans after infection (Halstead et al. 1973)  when sequentially infected with 
more than one serotype of DENV. The antibody response was targeted at the 
primary infecting serotype in these primates (Marchette et al. 1973). There 
were also higher levels of viremia during secondary infections, probably due 
to ADE in the NHPs (Koraka et al. 2007). Recently it has been reported that 
Rhesus macaques when infected i.v. with 1x10
7
 pfu of DENV showed signs of 
haemorrhage after 5 days post infection (Halstead et al. 1973). The NHP 
models have also been used to test potential therapeutics such as anti-virals 
and in predicting the infectivity, replication kinetics and immunogenicity of 
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live-attenuated vaccines and tetravalent vaccines (Onlamoon et al. 
2010;Durbin et al. 2011).  
Even though the NHP models can sustain viral replication and produce a 
robust antibody response, the lack of prominent clinical features, poor 
response from T cells and the logistical difficultly, economical and ethical 
constrains in conducting experiments on monkeys compared to a small animal 
model such as mouse makes this model less popular.  
1.3.2 Immune-competent mouse models 
In the first attempt to develop a small animal model for dengue, DENV was 
adapted to mice by inoculating them into the cerebrum of suckling immune-
competent mice and serially passaging from brain to brain. Over time, the 
mouse adapted virus strain produced increased neuro-virulence in the mice 
(Osorio et al. 2011). This model has been widely used to test the efficacies of 
a number of proposed dengue vaccines (Sabin and Schlesinger 1945). In the 
last decade, infection of adult immune-competent strains of mice such as A/J, 
BALB/c and C57BL/6 mice was performed with very high doses of mouse 
adapted strains of DENV (up to 3 x 10
9
 pfu) (Kaufman et al. 1987); 
(Atrasheuskaya et al. 2003). These infections resulted in thrombocytopenia, 
liver and endothelial damage, but showed low levels of viral replication with 
no significant signs of disease and the mice died of paralysis.  In another 
model, a mouse adapted DENV was shown to have high levels of viral 
replication and severe lethal disease by day 7 post infection in the immune-
competent mice (Shresta et al. 2004). There were also reports of establishing 
some disease symptoms by using non-mouse adapted viral strains (Costa et al. 
2012) though they did not support high levels of viral replication.  
25 
 
Although the immunocompetent mice are good models for testing the immune 
response to subunit vaccines (Chen et al. 2007); (Clements et al. 2010) the 
results may not be relevant to human disease as neuro-virulence or nervous 
system involvement in dengue infections is quite rare in humans. Due to the 
low infection levels in the mice and usage of mouse adapted strains, these 
models cannot be used to test the immune response of vaccine candidates like 
live attenuated viruses.  
1.3.3 Immune-compromised mouse models 
In the immune-compromised system, AG129 is the most popular mouse strain, 
which lacks the major cells of the immune system such as T cells, B cells, 
complements and importantly IFN,  and  components or receptors (also 
known as IFN knockout mice). AG129 mice when infected i.v with non-
mouse adapted DENV showed presence of virus in non-neuronal and neuronal 
tissues with signs of increased vascular permeability but absence of paralysis 
(Mellado-Sánchez et al. 2005). Infection of these mice with a high dose of 
another non-mouse adapted DENV i.p, lead to cytokine storm, massive organ 
damage, severe vascular leakage leading to haemorrhage and rapid death at the 
peak of viremia while the mice exhibited asymptomatic infection with non-
paralytic death at low doses (Shresta et al. 2006). It was also reported that s.c 
route of infection was more potent than i.p with   higher viral titres and earlier 
deaths (Tan et al. 2010). AG129 mice  were also used by other groups to 
demonstrate the mechanism and pathogenesis of antibody dependent 
enhancement (ADE) in vivo (Tan et al. 2011), (Balsitis et al. 2010) and to test 
anti-viral drugs (Zellweger et al. 2010). Another widely used immune-
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compromised mouse strain to study dengue infection is the A/J mice, which 
lack the complement component C5 (Schul et al. 2007;Shresta et al. 2004). 
Even though the immune-compromised mice have been used extensively for 
many studies there are still certain disadvantages. First of all, due to the lack 
of IFN,  and  receptors, a complete immune response to the DENV or the 
therapeutics cannot be generated. Thus the results obtained from the immune-
compromised mouse model systems cannot be translated to an immune-
competent system as in humans. Secondly, death occurs in most of the mice, 
while in humans, fatality is not commonly observed. And finally, even though 
some of these models exhibit typical severe dengue symptoms such as plasma 
leakage, other symptoms such as thrombocytopenia and leukopenia are not 
observed in these models. 
A search for an animal model which can recreate the disease symptoms and 
host-viral interactions as it occurs in humans, but still retains the advantages of 
a small animal model, is still underway. The recent establishment of 
humanized mouse models may attempt to full-fill some of the major 
requirements of the ‘ideal’ animal model and provide answers to understand 
the complex disease pathogenesis of dengue infection. 
1.4 HUMANIZED MOUSE MODEL 
‘Laboratory’ mice are usually the preferred model for in vivo studies, owing to 
their small size and experimental feasibility. However, the 65 million years of 
evolutionary divergence between mice and human, makes the mice 
considerably different from humans in their haematology and immunology 
(Huang et al. 2000). Therefore, the results obtained in the mice cannot be 
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comparable when translated to human. Thus, when an animal model with a 
small integral part of a human milieu became possible - the concept of 
‘humanised mouse’ was born.  The “humanized mouse” is an immune-
deficient mouse in which human cells, genes or tissues are engrafted and 
grown in it. The most popular and widely used model is the ‘human immune 
system’ mice and ‘human liver’ mice. In the later pages, the term ‘Humanized 
mice’ refers to the mice engrafted with cells of the human immune system.  
1.4.1 Development of humanized NOD-scid Il2rg-/- (NSG) mouse 
Since the first description of an immune-deficient mouse or nude mutation, it 
took around four decades to fully characterize and develop a robust humanized 
mouse model. There are three main breakthroughs in the development of 
humanized mice (Mestas and Hughes 2004). The first is the development of 
mice having a CB-17 scid/scid mutation which had a severe defect in the 
prkdc gene resulting in defective double stranded DNA repair (Shultz et al. 
2007). The subsequent deficiency in the development of mature T and B cells 
allowed successful engraftment of human peripheral blood mononuclear cells 
(PBMC) (Bosma et al. 1983), fetal haematopoietic tissues (Mosier et al. 1988) 
and haematopoietic stem and progenitor cells (HSPC) (McCune et al. 1988) in 
these mice. Spontaneous generation of mouse T and B cells and high levels of 
host natural killer (NK) cells that reject engraftments resulted in low 
engraftment levels. Ultimately, a functional human immune system could not 
develop. Later, the addition of NOD (non-obese diabetic) background to the 
scid mutation proved to be a second breakthrough by supporting higher levels 
of engraftment of PBMCs (Lapidot et al. 1992), lower levels of NK cells, 
absence of leakiness or spontaneous development of endogenous T and B cells 
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and additional defects in innate immune system (Hesselton et al. 1995). 
However, they were still limited by their short life spans due to occurrence of 
lymphomas and residual activity of NK cells.  The third and the most 
important breakthrough was the introduction of targeted deletion mutations in 
the interleukin-2-receptor (IL-2r)  chain locus (Shultz et al. 1995). IL-2r  
chain locus is a crucial component of high affinity receptors which is required 
for the signalling of cytokines such as IL-2, -4, -7, -9, -15 and -21. These 
cytokines are indispensable for the differentiation, maturation, activation, 
homeostasis and proper development of T cells (IL-2,7,15) B cells (IL-7,21) 
and NK cells (IL-2,15) (Ito et al. 2002). Due to less competition from 
endogenous thymic precursors and reduced occurrence of lymphomas, these 
NSG mice harboured the highest level of engraftment of human cells (up to 6 
times higher compared to NOD/scid mice) and longest life spans (around 90 
weeks) respectively (Kovanen and Leonard 2004). Therefore, it became the 
most popularly used humanized mouse model to date. 
1.4.2 Hematopoietic stem and progenitor cells (HSPCs) 
Earlier, the NSG mice were engrafted with peripheral blood mononuclear cells 
(PBMCs) from adult blood. But as the PBMCs are mature human immune 
cells and only few stem cells are present in the blood, it resulted in poor 
engraftment. Due to the advancements in the isolation techniques, the 
significance of HSPCs came to be known. HSPCs are multipotent stem cells 
that can give rise to the two major arms of the human immune system – the 
cells of the lymphoid lineage and myeloid lineage (Figure 1.9). They are 
capable of generating all cell types of the hematopoietic system in the graft 
recipients as well as sustaining long term hematopoiesis. Thus, higher 
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engraftment levels were achieved in the mice when reconstituted with the 
HSPCs (Shultz et al. 2005).   
HSPCs can be recognised by the marker CD34 on their surface, which is a 
stage specific antigen and is expressed on both lineage non-committed and 
committed hematopoietic progenitors (Ishikawa et al. 2005) (Krause et al. 
1996). The expression of CD34 antigen is highest on early progenitors and the 
density progressively reduces as they mature. The CD34
high
 population 
includes cells which have the potential of long term repopulation of T, B, 
myelomonocytic and megakaryocytic cells in vivo while the CD34
low
 cells are 
population which contains lineage committed progenitors that have lost the 
long term hematopoetic activity both in vivo and in vitro (Bryder et al. 
2006).Among the CD34
high 
population, the antigen CD133 is expressed on all 
the non-committed CD34
+
 cell population and majority of CD34
+
 cells 
committed to the granulocytic/monocytic pathway (DiGiusto et al. 1994).  
However, the expression of CD133 appears quite early and is rapidly lost 
during differentiation. In a recent study it has also been reported that there is 




 that can 
reproducibly give rise to hepatocyte like cells both in vitro and in vivo (Yin et 
al. 1997). 
The richest sources of HSPCs are human cord blood and fetal liver with the 
latter containing very high numbers of CD34
+
 HSPCs and both have been 
extensively used to reconstitute immune deficient mice (Chen et al. 
2013;Ishikawa et al. 2005;Shultz et al. 2007;Watanabe et al. 2009). Adult BM 
or cytokine mobilized human peripheral blood also have been used for 
reconstitution, though however they are limited by their HSPC numbers (Chen 
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et al. 2013). Other fetal tissues are also known to engraft well but have not 
been fully characterized. Mice are usually irradiated before introducing the 
HSPCs to create a niche in their BM where the HSPCs can engraft (Shultz et 
al. 2005;Ishikawa et al. 2005). Both adult mice and new born pups have been 
used for humanization using several routes of injection such as facial vein, 
intra-cardiac, intra-hepatic or intravenous (i.v) (Shultz et al. 2005). 
 
Figure 1.9 Lineage of human HSPC. The human HSPCs give rise to the entire 
human immune system by differentiating into both - the myeloid arm, which is the 
innate immune system and the lymphoid arm, which is the adaptive immune system. 
The different cell types formed from the respective arms can be seen in the figure. 
 
1.4.3 Drawbacks in the humanized NSG mouse 
Even though the NSG mouse is the preferred model till date, it also has certain 
defects or drawbacks which are major hurdles in the utility of the humanized 
mice. The most significant of all is the poor induction of humoral responses, 
against exogenous antigens. The total human IgG concentration in the serum is 
10-100 fold lower than that of humans as well as the equivalent mouse IgG 
concentration in wild type mice (Shultz et al. 2007;Traggiai et al. 2004).  
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Though the B cells from these mice are functional and can produce sufficient 
amount of IgM and IgG in vitro, they fail to produce it in vivo without any 
enhancements done to the model (Ishikawa et al. 2005). Several hypotheses 
have been suggested to contribute for the poor antibody response. One reason 
is the mismatch between human TCR on T cells and mouse MHCs in the 
mouse thymus (Watanabe et al. 2009;Shultz et al. 2007). Due to this, the 
human T cells are selected on the MHCs expressed on the mouse thymic cells, 
resulting in an improper selection. A direct effect of this is on the T cell 
dependent antibody response. Another possible cause is the poor development 
and maturation of human professional antigen presenting cells such as 
dendritic cells and macrophages (Legrand et al. 2006) (Watanabe et al. 2009). 
There are also evidences that the B cell development is blocked at the 
transitional stage where there is biased development of B1 lineage cells 
(which can produce IgM) but not the B2 lineage (which can produce IgG), 
with a significant proportion of B cell progenitors being accumulated in the 
spleen (Chen et al. 2012;Matsumura et al. 2003;Watanabe et al. 2009).  
There are also some abnormalities reported in the T cells even though they 
develop with a normal phenotype. These include high susceptibility to cell 
death in vitro and failing to proliferate or produce IL-2 in response to 
antigenic stimuli due to the hindrance of the mouse environment in the 
maintenance of human T cells (Chen et al. 2012). Mostly importantly, as the 
human T cells are positively selected in the mouse thymus they lose their 
function in the periphery leading to a poor immune response to antigens. 
Adding to it is the lack of an immunological architecture and fundamental 
components of the anatomy of the immune system in these mice. Some of 
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these are inconsistent development of a well-defined or developed lymphatic 
system, lack of normal T and B cell zones in the spleen and the incomplete 
formation of thymic cortex where negative selection occurs, leading to 
improper selection of human T cells (Watanabe et al. 2009;Shultz et al. 2007). 
This further adds to the failure to generate a robust and specific antibody 
response against antigens as the cells are not provided with the anatomical 
contexts within which they usually interact to elicit a response. Another 
drawback is the deficiency of several human cell specific cytokines resulting 
in lesser reconstitution of cell types such as NK cells or monocytes and 
blockage of T and B cell maturity (McCaughtry et al. 2008;Chen et al. 2009). 
Additionally, these mice also lack human granulocytes, erythrocytes and 
complement factors in their circulatory system (Chen et al. 2012). 
Research is still in progress to overcome these defects in the mice and there 
have been some improvements till date. One of them is the introduction of 
human fetal liver and thymus along with the HSPCs from the same fetus 
(abbreviated as BLT mice). These mice could mount antigen specific T cell 
responses during EBV infection (Shultz et al. 2007). Transgenic replacement 
of mouse co-stimulatory and MHC molecules could also be done with human 
HLA molecules so that proper positive and negative selection of T cells could 
occur. Another possibility is to create a conducive environment for the 
development of various cell types in the mouse by supplementing with human 
cytokines. This was achieved to an extent through a method developed in our 
lab where plasmids containing genes of human cytokines where introduced 
into the mice through hydrodynamic injection. This process results in the 
drastic increase of that particular cytokine in the mice and therefore improves 
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the development of specific target cells in the blood (Melkus et al. 2006). This 
method helps to significantly increase the reconstitution of human NK cells, 
monocytes, B cells and even erythrocytes. Recently, it was also shown that 
antibody response in the humanized mice can be improved by increasing the 
levels of GM-CSF and IL-4 which in turn promotes T, B and dendritic cell 
maturation (Chen et al. 2009). Despite these constrains, humanized NSG mice 
have been used for studying human immunity and its related diseases which 
are described in the section below. 
Disease models of the humanized NSG mouse 
The absence of a robust animal model had been an impediment in the study of 
many important infectious diseases like AIDS, malaria, filarial or dengue 
infection. It is because of the fact that most of the pathogens that can infect 
humans do not infect mice or any other laboratory animals in their wild state. 
And even if they do, the immune response to the diseases in these models 
could not be studied in a human cell context. Thus, the development of 
humanized mice tremendously accelerated the research and development of 
drug or vaccine for these diseases. The ability of the pathogens to infect the 
humanized mouse and generate an immune response is reported for diseases 
like AIDS (Chen et al. 2012), EBV (McCune et al. 1991),  Hepatitis- C (Islas-
Ohlmayer et al. 2004), malaria (Kneteman et al. 2006), filariasis (Morosan et 
al. 2006), tuberculosis (Nelson et al. 1991) and dengue (which will be 





1.5 HUMANIZED MOUSE MODELS OF DENGUE 
In the earliest described humanized mouse dengue model, human PBMC were 
used to engraft mice which were infected with DENV (Nelson et al. 1991). 
This model showed the presence of the virus in various tissues as well as the 
production of human IgG. Drawbacks of the mice with scid mutation (which 
was discussed earlier) and lower levels of engraftment, resulted in lower 
frequency of infection and lesser viral load in the blood. There were also no 
clinical signs in these mice which could be because of insufficient levels of 
target cells in the PBMCs. Later, monocytic (Wu et al. 1995) and hepatic (Lin 
et al. 1998) cell lines were engrafted in the hu-SCID model which when 
infected with DENV, developed sustained infection with viral presence in 
different tissues. The virus infected the engrafted tumour cells and then 
proceeded to the brain, resulting in paralysis and even death (An et al. 1999). 
The model could be used for testing therapeutics, but it could not be used for 
understanding the pathogenesis of the disease because of the irrelevant 
tropism. Moreover, tumours and cell lines do not mimic the actual human 
immune cells and the host immune response cannot be studied due to the 
absence of other components of the human immune system. 




 backgrounds, the 
mice were engrafted with  HSPCs from cord blood and DENV infections were 
carried out. In the NOD/scid model (Martina et al. 2009), there were 
manifestations of clinical signs in the mice. However there was no host 
immune response in the model and early deaths due to the defects in the strain 




 (Bente et al. 2005), although 
viremia and antibody response were shown in the mice, there were no 
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manifestation of clinical signs and the level of response in different mice were 
inconsistent. 
There are reports of dengue infection in the NSG mice reconstituted with 
HSPCs from cord blood.  In one of the infection models (Kuruvilla et al. 2007) 
the pups were reconstituted with 300,000 purified CD34
+
 cells. After 6-
8weeks, the mice were s.c infected with 1x10
6 
pfu/ml of lab adapted strain of 
DENV. Clinical signs such as fever, total platelet drop, rash (measured by 
increase in the redness of the skin) along with persistent viremia up to 18 days 
were detected in the infected mice. In their subsequent work, they showed 
infection in cells from BM, spleen and blood, along with cytokine profiling of 
the infected mice (Mota and Rico-Hesse 2009).  However, the presence of 
dengue antibodies was only seen in some of the mice that were infected with a 
highly virulent strain. There was also no significant increase in cytokines after 
infection and the response from human immune cells in the infected 
humanized mice were not reported. In their recent work (Mota and Rico-Hesse 
2011), the virus was introduced into the mice through the bite of a mosquito. 
This delivery route resulted in more severe disease with thrombocytopenia, 
production of IFN and other immune-modulators in the infected mice. 
In a study from another group (Cox et al. 2012), young adult mice between 6-
10 weeks were reconstituted with T cell depleted cord blood PBMCs (with at 
least 30,000 CD34
+
 cells. After 3 months of reconstitution, they were infected 
s.c or intra-peritoneally (i.p) with 1x10
6
 pfu of virus. Viremia was detected 
until 21 days and viral antigens were detected in various organs, although the 
viremia levels were not quantified. Clinical signs such as thrombocytopenia, 
rash or liver damage were not observed or reported. However, IgM was 
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detected in some of the mice and human T cells isolated from the humanized 
mice were able to secrete IFN-, IL-2 and TNF- in response to stimulation 
from DENV antigens. Humanized BLT-NSG mice were infected with DENV 
in a recent publication from the same group (Jaiswal et al. 2009). Dengue 
specific IgM antibodies were secreted by B cells isolated from the infected 
mice which had been immunized with dengue and there was an IFN response 
from the isolated T cells upon antigenic stimulation.  
The advantage of the humanized mouse model of dengue infection is the 
possibility to study the dengue disease pathogenesis in a human cell context. 
There are different kinds of humanized mouse model for dengue to date, still 
improvements have to be constantly made until a robust and stable model 
which can recapitulate the disease both in manifestation and immune response 




1.6 SCIENTIFIC OBJECTIVES 
The overall aim of this thesis study was to establish a DENV infection model 
in the humanized NSG mouse, which was constructed by adoptive transfer of 
fetal liver CD34
+
 cells into NSG mice. 
The specific aims of this study were 
i. To establish dengue virus infection in a humanized mouse model 
with human immune cells, platelets and hepatocytes 
ii. Use the model to investigate the mechanism behind DENV induced 
human thrombocytopenia in the humanized mice 
iii. Use the model to analyse a single nucleotide variation in the 
DENV genome that could cause a change in replicating efficiency 































2.1  GENERATION OF HUMANIZED MICE 
2.1.1 Isolation of fetal liver HSPCs 
Human fetal liver were obtained from 14-24 week old aborted fetuses, and 
HSPCs were isolated from it. Collection of fetal tissue for research is 
approved by the Research Ethics Committee of NUH complying with 
National guidelines (Singapore) for use of fetal tissue in research. Written 
consent for the clinically indicated procedure and use of fetal tissue for 
research was obtained from the pregnant women before abortion.  
The aborted fetuses were collected within 2 hours from the point of delivery 
and the fetal liver was immediately dissected. The tissue was cut into small 
pieces and digested with collagenase IV (2mg/ml) at 37C for 15 minutes with 
gentle agitation.  To make single cell suspension it was then passed through a 
100m cell strainer (BD Biosciences) and subsequently the residual RBCs 
were lysed using ACK lysis buffer (GIBCO) for 10 minutes. The suspension 
was washed twice to get rid of platelets. Then the CD34
+
 cells (a universal 
marker for HSPC) were then isolated from the mononuclear cells (MNC) 
using the Automated Robosep
®
 system according to the manufacturer’s 
protocol (Stem Cell Technologies). Depending on the age of the foetus during 
abortion, the number of HSPCs obtained ranges between 20 x 10
6
 – 150 x 106 
cells. The cells were resuspended in StemSpan medium (Stem Cell 
Technologies) and frozen 1:1 with a freezing medium (75% FBS + 25% 
DMSO) at -80C. All the procedures were done under sterile conditions. 
The purity of the cells obtained was assessed by flow cytometry. The cells 
were directly stained with the flurophore conjugated antibodies against human 
CD45 (hCD45), hCD34 and hCD133 using the protocol described in section 
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2.4.6, page 41. More than 95% of the cells are generally CD34
+
 out of which 
atleast 30% of them are positive for CD133. 
2.1.2 Humanization of mice 
NSG mice were purchased from the Jackson Laboratory and maintained under 
specific pathogen free conditions in the animal facility at NUS. To reconstitute 
mice, new born pups within 48 hours old were sublethally irradiated with 
100cGy using an X-Ray irradiation source.  HSPCs were retrieved from -
80C, thawed in 37C water bath, washed and 2×105 CD34+ cells were 
resuspended in 50l per pup in StemSpan medium and injected intra-
cardiacally into the pups. All research and procedures done on mice were 
performed in accordance to the institutional guidelines and under sterile 
conditions. 
2.1.3 Calculation of engraftment levels in humanized mice 
The engraftment levels or reconstitution was checked when the mice were 10-
12 weeks of age. Whole blood and single cell suspension were prepared as 
described later. The single cell suspensions were then stained with fluorophore 
conjugated antibodies for hCD45, mouseCD45.1 and hCD14. The percentage 
of reconstitution was calculated using the formula: 
                  
                  
                                      
 





2.2 VIRUS GROWTH AND QUANTIFICATION TECHNIQUES 
All the procedures were done under sterile conditions. 
2.2.1 Production of DENV2 virus in mosquito cell line C6/36 
Aedes albopictus mosquito cell line (C6/36) was grown and maintained as a 
confluent monolayer in RPMI 1640 medium (GIBCO) with 10% fetal bovine 
serum (FBS) (Lonza) and 1% Penicillin/ Steptamycin/ Glutamine (GIBCO) at 
28˚C. DENV2 lab adapted strain New Guinea C (NGC) or a clinical isolate 
with a low passage number from early dengue study (EDEN DENV2 
07K2861) was incubated with the cells at an MOI of 0.01 for one hour at 37˚C 
with gentle shaking every 15 minutes. It was then removed and replaced with 
fresh RPMI 1640 medium supplemented with 2% FBS. The virus was allowed 
to propagate on the cells for 4-5 days or until 75% of the cells showed 
cytopathic effect (CPE) and syncytium. The cell culture supernatant was 
collected and concentrated.  
2.2.2 Concentrating the virus 
The cell culture supernatant of the infected C6/36 cells was centrifuged at 
2000rpm for 10 minutes to get rid of the cell debris. Subsequently, 50ml of the 
supernatant was loaded onto the Vivacell 100 centrifugal concentrator 
(Sartorius) and centrifuged at 2000g for 10 minutes. The flow through was 
discarded and the cell culture supernatant remaining in the concentrator was 





2.2.3 Titrating the virus using plaque assay 
For quantification of the virus, BHK-21 cells were cultured until confluency 
with RPMI 1640 medium with 10% FBS and 1% Penicillin/ Steptamycin/ 
Glutamine in 24 well plates at 37˚C. The virus was retrieved from -80C, 
thawed in 37˚C water bath and serially diluted in serum free media. It was 
then inoculated with the cells at 37˚C with gentle shaking every 15 minutes for 
one hour. The medium was replaced with the overlay medium (RPMI 1640 
medium containing 2% Carboxymethyl cellulose and 2% FBS) and incubated 
at 37˚C. After 5 days the cells were fixed with 3% formalin in PBS for 1 hour, 
washed and stained with 0.1% crystal violet in 10% formalin solution for 1 
hour (or overnight) at room temperature. The plates were washed and the 
plaques were counted. In 1 pfu of the cell culture supernatant around 1000 
copies of viral RNA could be quantified through quantitative real time PCR 
(qRT-PCR). 
2.3 INFECTION OF HUMANIZED MICE 
The pre-selected humanized mice were injected i.v with 1x10
7
 pfu of the 
concentrated virus in 200μl of RPMI 1640 medium through tail vein. In one 
experiment, 1x10
7
 pfu/mouse of the virus was incubated with 0.49g of the 
humanized antibody 4G2 (per 10
7
 pfu) at 37C for one hour, and then injected 
i.v into the humanized mice.  As control, humanized mice reconstituted with 
the same batch of human fetal liver HSPCs were injected with plain RPMI 
1640 media. In some experiments, virus was heat inactivated (at 60C for 1 
hour) and then injected into the humanized mice as control. For statistical 
analysis, the number of mice in each group was kept to at least 5 in number. 
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To avoid variability in different fetal liver samples, experiments were repeated 
with different batches of human fetal liver HSPCs reconstituted mice. The 
infected mice were regularly checked and their condition was noted. If they 
became morbid, they were immediately euthanized for analysis. All 
procedures done on the mice were performed in accordance to the institutional 
guidelines and under sterile conditions. 
2.4 ANALYSIS OF INFECTION 
2.4.1 Bleeding of the mice  
When small volumes of whole blood from infected or uninfected mice were 
required, they were bled at various time points through facial vein bleeding 
using a 21 gauge needle. Whole blood was collected in a Greiner Bio-one 
EDTA Vacuette
® 
tube containing K3EDTA and was mixed well to avoid 
clotting. After taking the required volume for platelet counting, they were 
centrifuged at 350g for 7 minutes; plasma was collected and stored at -20C 
for various analyses. Single cell suspension of the residual cells after 
collection of plasma was done as described later. 
2.4.2 Harvesting tissues from mice 
The mice were euthanized in a CO2 chamber and whole blood was collected 
using a 27 gauge needle fitted to a 1ml syringe via cardiac puncture. 300l of 
blood was collected in an empty 1.5ml tube to isolate serum and rest were 
collected in Greiner Bio-one EDTA Vacuette
® 
tubes containing K3EDTA and 
mixed well to avoid clotting. For extracting the serum, the blood was allowed 
to clot at room temperature for 30 minutes and centrifuged at 200g for 7 
minutes. The serum was collected, aliquoted and stored at -20C for various 
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analyses. After taking the required volume for platelet counting, the blood in 
EDTA tubes were centrifuged at 350g for 7 minutes and the plasma was 
collected and stored at -20C for various analyses. Single cell suspension of 
the residual cells after collection of plasma was prepared for flow cytometry 
analyses. 
The mice were dissected afterwards and the changes in tissue morphology 
were recorded. For histology, one lobe of the liver was cryo-preserved in Jung 
tissue freezing medium (Leica biosystems) and snap frozen in liquid nitrogen 
or kept on dry ice for 1 hour. The samples were then transferred to -80C for 
long term storage. For RNA extraction, less than 30mg of liver, spleen and 
axillary LNs were collected and stored in RNAlater stabilization reagent 
(Qiagen) at -20C. For the BM in particular, one femur was flushed and single 
cell suspension were prepared, lysed with 600l RLT lysis buffer (RNeasy 
mini kit, Qiagen) and stored at -20C. For flow cytometry analyses, the rest of 
the liver, spleen, LNs and one femur of the BM were stored in RPMI 1640 
medium on ice. 
In some experiments, liver homogenates were made, to isolate the viral 
particles from the infected mice for amplification in C6/36 mosquito cell lines. 
A small part of the liver was taken in a 1.5ml tube with RPMI 1640 and 
homogenized using stainless steel beads (5mm) in Qiagen TissueLyser LT 
with maximum speed for 10 minutes at 4C. The homogenate was then 
collected, centrifuged at 2000rpm for 10 minutes to pellet the debris and the 




2.4.3 Extraction of RNA and qRT PCR  
Virus quantification in organs: To detect viremia in the serum, 140l of serum 
was used to extract viral RNA using QIAamp viral RNA mini kit (Qiagen) 
according to the manufacturer’s instructions. The RNA was eluted in 30l and 
stored at -80C. To detect the viral load in the liver, spleen and LNs which 
were stored in RNAlater, the respective tissues were weighed and 
homogenized in 600l of RLT lysis buffer (RNeasy mini kit, Qiagen) using 
stainless steel beads (5mm; one bead per sample), in the Qiagen TissueLyser 
LT with maximum speed for 10 minutes at 4C. The RNA was extracted using 
the RNeasy mini kit (Qiagen) according to the manufacturer’s instructions, 
eluted in 30l and stored at -80C. 
The extracted RNA was converted to cDNA and amplified using one step 
qRT-PCR based QuantiFast Probe RT-PCR Kit (Qiagen) according to the 
manufacturer’s instructions. Forward and reverse primer sequence for the viral 
E protein used were 5'-ACA CCA CAG AGT TCC ATC ACA GA-3` and 5'-
CAT CTC ATT GAA GTC NAG GCC-3' respectively in a final concentration 
of  0.4 mM with  melting temperature of 60C. The FAM conjugated probe 
sequence used was CGA TGG AAT GCT CTC at 0.2mM concentration. 
Three l of the RNA template was used per reaction. The sensitivity of the 
qRT-PCR was around 100 copies. 
The synthetic DNA with the sequence  5`-ACA CCA CAG AGT TCC ATC 
ACA GAA GCA GAA CTA ACA GGC TAT GGC ACT GTC ACG ATG 
GAA TGC TCT CCG AGA ACG GGC CTC GAC TTC AAT GAG ATG-3` 
(which contains the sequence of both the primers and probe) was used to plot 
46 
 
the standard curve. Copy numbers of the synthetic DNA were calculated, 
adjusted to 10
7
 copies and serially diluted to achieve the standard curve. qRT-
PCR was performed using CFX96 Real Time System (Bio-rad).  
Measurement of relative hTPO gene expression in liver: Total RNA was 
extracted from the liver of NSG mice, uninfected and infected humanized 
mice and human FL. The amount of RNA was quantified using Nanodrop 
1000 (Thermoscientific). 1mg of mRNA was converted to cDNA using iScript 
cDNA Synthesis Kit (Bio-Rad) and was amplified using the SsoFast Eva Low 
Rox kit (Bio-Rad) as per manufacturer’s instructions in the CFX96 Real Time 
System (Bio-rad) and the specificity was tested by using the melt curve 
analysis. The forward and reverse primers used for hTPO were 5`- ACT GCA 
AGG CTA ACG CTG T-3` and 5`- GAC ATG GGA GTC ACG AAG CA-3` 
respectively, and for hGAPDH were 5`- CGC CCC ACT TGA TTT TGG A-
3` and 5`- TTG CCA TCA ATG ACC CCT TCA-3` respectively at a melting 
temperature of 57C. The DNA product was confirmed by running a 2.5% 
agarose gel.  
2.4.4 Isolation of virus from infected humanized mice and amplification 
in C6/36 cell line 
Serum and liver homogenate from infected mice were diluted in plain RPMI 
1640 to a final volume of 1ml and incubated with a monolayer of C6/36 
mosquito cell line for one hour at 37C with gentle shaking every 15 minutes. 
The medium was then removed and replaced with 5 ml of fresh RPMI 1640 
medium with 2% FBS and kept in a 28C incubator for 5 days. The 
supernatant was then removed and centrifuged at 2000rpm for 10 minutes. 
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100l of the supernatant was taken for plaque assay and RNA extraction 
respectively, and the rest was loaded to a VIVASPIN 20 (Sartorius). The 
supernatant was centrifuged at 5000g for 5-7 minutes until only 1ml of the 
medium remained. It was then incubated with a monolayer of C6/36 mosquito 
cell line and the protocol was followed as above. This was repeated for a total 
of 3 rounds of amplification. 
2.4.5 Counting of platelets through flow cytometry 
10l of whole blood of the infected or uninfected humanized mice was taken 
in a 5ml polystyrene tube (BD) in 600l Flow Cytometry (FC) buffer – 1X 
PBS, 0.5 % BSA and 0.02% Sodium Azide. The fluorophore conjugated 
antibodies against human CD41 and mouse CD41 (Table 2.1) were added to it. 
After incubating for 10 minutes, 25l of CountBright™ Absolute Counting 
beads (Invitrogen) were added and analysed in LSR II flow cytometer 
(Beckton Dickinson) until 1000 beads events were recorded per sample. The 
number of human or mouse platelets were calculated using the formula: 
                                       (
                       
           
  
            
   
) 
2.4.6 Immuno-phenotyping and sorting of cells and organs by flow 
cytometry 
Preparation of single cell suspensions of organs: The red blood cells (RBC) of 
the whole blood of the infected or uninfected humanized mice were lysed with 
1ml ACK lysis buffer for 10 minutes. They were then washed and stained with 
respective flurophore conjugated antibodies (Table 2.1). Liver was grinded 
through a 100m stainless steel mesh in RPMI 1640 medium and centrifuged 
at 50g for 5 minutes to remove the hepatocytes. The pellet was then 
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resuspended in 40% Percoll solution (GE Healthcare) and gently laid over a 
70% Percoll solution. It was then centrifuged at 750g for 30 minutes without 
applying brakes. The layer of mono nuclear cells formed between the two 
interfaces was carefully removed, washed and stained with respective 
flurophore conjugated antibodies (Table 2.1). Spleen or LNs were gently 
mashed between the coarse surfaces of two glass slides in RPMI 1640 medium 
and filtered through 100m nylon mesh (SEFAR). Only for the spleen 
samples the RBCs were lysed by incubating with ACK lysis buffer for 10 
minutes followed by washing with 1xPBS. After filtering again the single cell 
suspension of the spleen and LNs were stained with respective fluorophore 
conjugated antibodies (Table 2.1).  The heads of the femurs were cut and the 
BM was gently flushed out using RPMI 1640 medium with an insulin syringe. 
Clumps of cells were again broken down by aspirating in and out of the insulin 
syringe. The RBCs were lysed by incubating with ACK lysis buffer for 10 
minutes and washing with 1xPBS. After filtering with 100m nylon mesh, the 
single cell suspension was stained with respective flurophore conjugated 
antibodies (Table 2.1). All washing steps were done by re-suspending the cells 
in 10ml FC buffer and centrifuging at 350g for 7 minutes. 
Staining with flurophores: The single cell suspensions of various organs were 
suspended in 60-80l of FC buffer and stained with the respective flurophore 
conjugated antibodies (raised in mice), for 15 minutes (Table 2.1). The 
conjugated antibodies with the flurophores FITC, PE, APC or PE/Cy7 were 




Table 2.1 List of markers for various cell types used in 
immunophenotyping of organs by flow cytometry and their respective 
clones of antibodies  
Target cell 
Marker 
(Antibody conjugated to 
flurophore) 
Biolegend Clone 




Human leukocytes CD45 HI30 
Mouse leukocytes CD45.1 A20 
Human monocytes CD14 HCD14 
Human B cells CD19 HIB19 




Human NK cells CD56 HIT56 
Human DCs CD209 9E9A8 







The cells were washed by re-suspending in 10ml FC buffer and were 
centrifuged at 350g for 7 minutes. After resuspending in FC buffer containing 
DAPI, which is used as a viability stain they were immediately analysed in 
LSR II flow cytometer (Beckton Dickinson). The stopping gate was set at 
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1,000,000 live cell events for blood cells and 100,000 live cell events for all 
the other organs. The data was analysed using the FlowJo software (FlowJo). 
Sorting of cells: For sorting of megakaryocytes, single cell suspensions were 
prepared from the BM as described before and resuspended in 100l. It was 
first incubated with 10l of human FcR blocking antibody (Stem cell 
technologies) and 1l of mouse FcR blocking antibody (Stem cell 
technologies) for 2 minutes and stained with hCD41 and mCD41 antibodies as 
described earlier. It was then resuspended in FC buffer containing DAPI at a 
concentration of 1x10
7
 cells per ml and sorted using the FACS Aria cell sorter 
(BD Biosciences) into poly propylene tubes containing 1ml of StemSpan 
medium for cell culture or 600l RLT lysis buffer for RNA extraction. Cell 




2.4.7 Measuring ALT, AST and haematocrit values in blood 
40l of whole blood from infected or uninfected humanized mice were 
collected in capillary tubes for measuring the haematocrit value and 80l of 
serum was used to measure ALT and AST using Cobas C111 Analyzer 
(Roche) in Comparative Medicine in-house veterinary diagnostic laboratory, 
NUS.  
2.4.8 Histology techniques 
Sections of 5m thickness were cut from the liver lobes frozen in OCT using a 
cryostat (Leica), and laid on polylysine coated slides and stored at -20C. The 
slides were air dried for 3 hours and proceeded with different staining 
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techniques. All washing steps were done by placing the slides 3 times in 
1xPBS for 5 minutes. 
Immunofluorescence (IF)/ Immunohistochemistry (IHC): The dried slides were 
fixed with ice cold 75% acetone and 25% ethanol for 5 minutes. Then they 
were washed with 1xPBS and blocked with 3% BSA and 0.02% Triton X 100 
in 1xPBS for 30 minutes at room temperature.  
For IF, the primary antibody, 4G2 (D1-4G2-4-15 (ATCC, HB-112) anti dengue E 
(raised in mouse) was incubated with the slides with 1:10 dilution at 4C over 
night. After washing with 1xPBS, they were then stained with the Alexa fluor 
488 anti-mouse secondary antibody, raised in donkey (Invitrogen) for 1 hour 
at room temperature. They were washed again with 1xPBS, stained with 
SlowFade® Gold reagent with DAPI (Invitrogen) for staining the nucleus and 
covered with a glass cover slip. The stains were then scanned and visualized 
with MIRAX MIDI Fluorescence microscope (Zeiss). 
For IHC, the primary rabbit anti-human albumin (Abcam) was incubated with 
the slides at 1:100 dilution at 4C over night. After washing with 1xPBS, the 
endogenous peroxidases were inactivated by using 3% H2O2 for 10 minutes. 
Sections were then rinsed in deionized water and washed in 1xPBS. The slides 
were incubated with HRP polymer conjugate for 5 minutes at room 
temperature, washed with 1xPBS and incubated in DAB solution for 5 minutes 
at room temperature. After washing with 1xPBS, the slides were wiped dry 
and a mounted with Permount medium (Fisher Scientific). The slides were 




Hematoxylin & Eosin (H & E) staining: The dried slides were stained with 
hematoxylin solution for 5 minutes, washed in deionized water and 
differentiated using the differentiating fluid for 10-30 seconds. After rinsing 
with deionized water, and washing 3 times in tap water (for 5 minutes each), 
the slides were stained with aqueous eosin for 5 minutes. They were serially 
dehydrated in an increasing concentration of ethanol (from 70-100%). A final 
wash is given by incubating with histoclear solution for up to a minute. Then 
the slides were mounted with Permount medium and scanned using a MIRAX 
MIDI Bright field microscope. 
2.4.9 Western blot technique 
C6/36 cells incubated with serum or liver homogenate from infected mice (7 
dpi) or viral cell culture were lysed with 2×Laemmli sample buffer containing 
bromophenol blue and the protein concentration was determined by the Bio-
rad Protein Assay kit. 4µg of protein was separated by using 10% SDS-PAGE 
and transferred to a nitrocellulose membrane (Bio-rad) using the wet transfer 
technique. The membrane was blocked with 5% skim milk in 1xPBS 
(blocking buffer) for 1 hour at room temperature and incubated with rabbit 
anti-dengue NS1 primary antibody (Genetex) (1:1000 in blocking buffer) 
overnight at 4°C. The membranes were washed and subsequently incubated 
with HRP-conjugated anti-rabbit secondary antibody (Dako) (1:3000 in 
blocking buffer) for 1 hour at room temperature. Detection was performed 
using the enhanced chemiluminescence (ECL) prime detection reagents (GE 
healthcare). 
2.4.10 Measuring specific proteins or antibodies by sandwich ELISA 
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Dengue specific IgG and IgM antibodies : The presence or absence of the 
antibodies were measured at various time points in the serum of the infected or 
uninfected humanized mice using the Panbio Dengue IgG Capture enzyme-
linked immunosorbent assay (ELISA) kit and Panbio Dengue IgM Capture 
ELISA kit according to the manufacturer’s instruction.  
Human serum albumin: Serum was collected from the infected or uninfected 
humanized mice as described before. 50-100l of serum was used to measure 
human serum albumin using the human albumin ELISA quantification set 
(Bethyl Laboratories Inc.) according to the manufacturer’s instructions. The 
absolute quantity of albumin was calculated from the amount of serum 
originally used for incubation. 
2.4.11 Sequencing data 
All DENV samples were sequenced in Genome Institute of Singapore, as 
described in (Jaiswal et al. 2012). Briefly, RNA was isolated, converted to 
cDNA, amplified, fragmented and a cDNA library was constructed. The whole 
genome of the virus was sequenced using the Hiseq deep sequencing 




2.4.12 Statistical analysis 
All graphs were plotted and statistical analysis was performed using GraphPad 
Prism-5 software and Microsoft Excel 2010. Fractional fold changes was 
calculated using the formula  
                        
(                                                       )
                           
 
The fractional fold change is represented as ‘fold change’ in all the graphs of 
this thesis. 
Pearson’s correlation was used for correlations between different sets of 
samples and Student’s t-test was used for testing statistical significance 
between various sample groups. p-values less than 0.05, 0.01 or 0.001 were 
considered to be 95%, 99% or 99.9% significant respectively. All error bars 


























CHAPTER 3: ESTABLISHING DENGUE INFECTION IN 




There are numerous animal models for dengue infection available at present 
each with its advantages. However, the major limitation in all the models is 
the inability to study the dengue disease pathogenesis in a human cell context. 
Thus the concept of humanized mice was development, which are immune-
deficient mice engrafted with human hematopoetic stem/progenitor cells. 
These mice develop human immune cells along with human platelets and 
human hepatocytes. This chapter will explain in detail the characterization of 
the humanized NSG mouse model for dengue infection. 
RESULTS 
3.1 GENERATION OF HUMANIZED MICE 
3.1.1 Isolation of fetal liver HSPCs 
CD34
+ 
cells were isolated from human fetal liver and their purity was assessed 
by flow cytometer using the markers human CD45, CD34 and CD133. The 
gating was performed based on size and granularity using the forward scatter 
(FSC) and side scatter (SSC) to gate in the mononuclear cells (MNC) followed 
by a DAPI (-) gating, where live cells exclude the DAPI stain. The cells were 
gated on the respective flurophores for CD34 and CD133 to get the percentage 




 (Figure 3.1).   
 
Figure 3.1 Gating strategies for selecting mononuclear live HSPCs. All the events 
are first gated based on FSC and SSC (MNC) from which DAPI
-
 cells are gated (live 




 cells) were selected. The numbers indicate 
percentages of cells in the gated regions. 
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3.1.2 Human cell reconstitution in humanized  mice 
Humanized mice were constructed by injecting 200,000 CD34
+
 cells isolated 
from human fetal liver into sub lethally irradiated new-born NSG pups. 
Twelve to fifteen weeks later PBMCs were analysed for mCD45, hCD45 and 
other markers. Similar to the gating strategy mentioned before, the PBMCs 
were first gated on FSC and SSC to gate in the MNCs followed by DAPI
-
 
gating. Subsequent gating was performed with the live cells. The gating on all 
the human immune cell populations was done on hCD45
+
 cells. The 
reconstitution rate of human leukocytes (chimerism) was calculated as 
follows: % hCD45
+
 / (% hCD45
+
 + % mCD45
+
). Humanized mice with 20% 
or more chimerism were used for subsequent experiments.  
Human immune cells: Analysis of 12-15 week old humanized mice showed 
reconstitution of human leukocytes in various organs such as blood, liver, 
spleen, axillary LN and BM (Figure 3.2 A). Among human leukocytes CD19
+
 
B cells and CD3
+




 subsets, were most 
abundant followed by CD14
+
 monocytes or macrophages and a low level of 
CD56
+
 NK cells (Figure 3.2 B and C). Notably, LNs, with up to 90-98% of 
human immune cells were also found in the humanized mice specifically after 
15 weeks of age (Figure 3.2 C).  
Human platelets: The humanized mice reconstituted with human fetal liver 
CD34
+
 cells (FL-NSG) developed human platelets in the blood, identified by 
marker hCD41. This could not be observed in the blood of humanized mice 
reconstituted with cord blood CD34
+
 cells (CB-NSG) or non-humanised mice 
(NSG) (Figure 3.3).  The gating for this experiment and all the following 
studies involving platelets was done on all events of the blood from 
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humanized mice. On an average, each humanized mouse had around 10
4
 
human platelets and 10
6 
mouse platelets in its blood. 
 
Figure 3.2. Characterization of human cell reconstitution in humanized mice. 
(A) Representative hCD45 versus mCD45 staining profiles of blood, spleen, LN, BM 
and liver gating on live cells (DAPI
-





 leukocytes among total MNCs. (B) Representative staining profiles for 
hCD14 versus hCD45, hCD19 versus hCD45, hCD56 versus hCD3, and hCD8 versus 
hCD4 gating on hCD45
+
 cells in various tissues. The numbers indicate percentages of 





), B cells (CD19
+
), T cells (CD3
+
), CD8 T cells (CD8
+
), 
and CD4 T cells (CD4
+
) in various tissues. Human leukocyte chimerism is also 







Figure 3.3 Human platelets in the blood of the humanized mice reconstituted 
with human fetal liver CD34
+
 cells.  Representative hCD41 versus mCD41 staining 
profile of whole blood of  humanized mice reconstituted with cord blood CD34
+
 cells 
(CB-NSG), with fetal liver CD34
+
 cells (FL-NSG) and non-humanized mice (NSG) 
(left). The numbers indicate percentages of cells in the gated regions. The average 
counts of human and mouse platelets per microliter of blood among 28 humanized 
mice (right).  
Human hepatocytes: Human hepatocytes were also found in the liver of 
reconstituted mice as indicated by histological staining for human albumin-
expressing cells in the liver sections (Figure 3.4A). Human albumin was also 
detected in the serum of the humanized mice detected through an ELISA assay 
for the same (Figure 3.4B)  
 
Figure 3.4 Presence of human hepatocytes in the humanized mice. (A) 
Representative IHC staining of human albumin of liver sections of humanized mice 
(scale bar - 100m) (B) Average values of the human albumin in the serum of 
humanized mice (FL-NSG, n=16) and plain NSG mice (n= 5) as measured by ELISA. 
3.2 OPTIMIZING INFECTION TECHNIQUES 
3.2.1 Viral clearance in non-humanized mice 
Before using the DENV2 strain NGC for infecting humanized mouse model, it 
was first verified whether it can infect the mouse cells in the ‘non-humanized’ 
NSG mice. A group of 12 week old non-humanized NSG mice were injected 
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i.v with NGC virus (1x10
7
 pfu) and viral levels in the serum, liver, spleen and 
BM were measured by qRT-PCR 10 minutes, 1 day post infection (dpi) and 
every 3 days until 30 dpi. Ten minutes post injection, viral RNA was detected 
in the serum, liver and spleen but not in the BM (Figure 3.5). After one dpi, 
viral RNA was detected only in the spleen and no viral RNA was detected in 
any of the tissues from 3 to 30 dpi, suggesting that infection with NGC virus 
occurs only in the presence of human cells in NSG mice. There were no LNs 
in the ‘non-humanized’ NSG mice. This indicates that the DENV2 NGC used 
cannot replicate efficiently in the mouse cells of the ‘non-humanized’ mice 
and might require human cells for replication. 
 
Figure 3.5 Clearance of NGC virus in the NSG mice without human cells. Plain 
NSG mice were injected i.v with 1x10
7
 pfu of NGC viruses. Three mice were 
sacrificed 10 minutes post infection, 1 or every 3 dpi until 30dpi. RNA was isolated 
from serum, spleen, BM and liver and used to measure viral RNA levels by qRT-
PCR. Viral copies per ml of serum, per mg of spleen or liver or per femur are shown. 
The mice were analysed every 3 dpi up to 30 dpi and viral particles were not found in 
all the organs up to 30 dpi. Each symbol represents serum or tissue from one mouse. 
The horizontal lines indicate the average viral copies in each tissue or serum collected 
from mice at the same dpi. The dotted lines indicate the sensitivity of PCR at 100 
copies. The numbers in parentheses indicate the number of mice with viral copies 







3.2.2 Choosing the dose and route of infection 
To mimic the actual route of infection 1x10
6
 pfu of NGC virus was injected 
s.c into 12-15 weeks old humanized mice. The mice were bled every 3 days 
and 30l of serum was taken to perform viral RNA extraction and qRT-PCR. 
However viral RNA could not be detected in the serum. The viral dose was 
then increased to 1x10
7
 pfu and injected s.c. Again, it did not result in 
detectable viral RNA in the serum. In both the experiments, non-reconstituted 




 pfu) also did not 
have detectable viremia in the serum. Nevertheless, when immunophenotyping 
of different populations was done in the blood, an increase in the number of 
hCD14
+
 monocytes could be seen in the infected mice with statistical 
significance after 6 dpi (Figure 3.6). This suggests that although the infection 
was not detected in the serum, there was a response from the human cells to 
the virus when injected s.c.  
 
Figure 3.6 Increase in hCD14
+
 frequencies in the blood after s.c infection with 
NGC.  Humanized mice injected with 1x10
7
 pfu of NGC virus s.c (n=5) or uninfected 
(n=3) were bled at the indicated dpi, PBMCs were stained for hCD14 and hCD45 and 
analyzed by flow cytometry. The count of the cells was also measured 
simultaneously. The number of hCD14
+
 cells of each mouse at various dpi was 
normalized to the number of the same mouse before infection. Shown are the 
averages and SEM over time. *p<0.05. 
62 
 
To exclude the probability that the number of viral particles in 30l of serum 
could be too low for detection, the mice infected s.c with 1x10
7
 pfu were 
euthanized and 140l of serum were taken for RNA extraction. (as 
recommended by QIAamp viral RNA mini kit’s (Qiagen) protocol). The viral 
RNA could not be detected after RNA extraction by RT-PCR. However, when 
1x10
7
 pfu of the virus was injected i.v into the humanized mice and 140l of 
serum was taken for RNA extraction, detectable viral RNA could be found in 
the serum of the infected humanized mice. Therefore the viral dose of 1x10
7
 
pfu and i.v route was selected for further experiments. Table 3.1 briefly 
summarizes the different doses and routes used and its corresponding 
outcomes. 
Table 3.1 Choosing the dose and route of infection along with the volume of 
serum taken for RNA extraction to get detectable viremia in serum 
VIRAL 
DOSE 
ROUTE Serum volume for 
detecting viremia 
Detection of viremia 




 pfu s.c 30ul Not detected 
1x10
7
 pfu s.c 30ul Not detected 
1x10
7
 pfu s.c 140ul Not detected 
1x10
7
 pfu i.v 140ul DETECTED 
3.3 INFECTION OF HUMANIZED MICE WITH DENGUE 
3.3.1 Viral load in different organs 
Humanized mice were infected i.v with 1x10
7
 pfu of the DENV2 NGC virus 
and euthanized at different dpi for analysis. Viremia in the serum was 
quantified by qRT-PCR for the E gene of the viral RNA. Viremia was detected 
in significant numbers of mice starting from 3 dpi, with a peak at 7 dpi and 
persisted until 28 dpi. Viremia could be detected only in one mouse by 49 and 
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63 dpi, respectively (Figure 3.7A). Viral load was also measured in the 
selected tissues at 7 dpi and significant levels could be detected in the liver, 
spleen, LN, and BM in approximately 50% of the infected mice (Figure 3.7B). 
In some fractions of mice viremia level was below the detection limit of the 
qRT-PCR (100 copies). Nevertheless, some infected mice with viremia below 
the detection limit had detectable levels of viral load in the tissues and vice 
versa (Figure 3.7C) suggesting that most of the mice were infected even 
though viremia could not be detected by qRT- PCR. However, all the mice did 
not show any signs of sickness such as lethargy, hunched posture or ruffled 
fur. Also to note is that since the organs were not perfused before dissection 
there might be a slight overestimation of the number of viruses, especially in 
highly vascularized organs such as spleen and the liver, due to the presence of 





Figure 3.7 Viremia in serum and viral load in different organs in infected 
humanized mice detected by qRT-PCR. Humanized mice were injected with 1x10
7
 
pfu of NGC virus i.v. Mice were sacrificed at the indicated dpi and RNA was isolated 
from serum, liver, spleen, LN and BM. The levels of viral RNA in different tissues 
were measured by qRT-PCR. Shown are viral copies per ml of serum at different dpi 
(A) and viral copies per mg of tissues or per femur at 7 dpi (B). Each symbol 
represents serum or tissue from one mouse. (C) Infected humanized mice with 
undetectable viremia in the serum (left) and detectable viremia in the serum (right) 
with their corresponding viral load in different organs showing that there is systemic 
infection even when in the mice with undetectable viremia. Each virus-infected 
humanized mouse on 7 dpi is shown with different symbols so as to track individual 
mice. The horizontal lines indicate the average viral copies in each tissue or serum 
collected from mice at the same dpi. The dotted lines indicate the sensitivity of PCR 
at 100 copies.  The numbers in the parentheses indicate the number of mice where 
viral copies were below the detection limit 
3.3.2 Viral particles isolated from humanized mice are infectious 
To show the presence of infectious virus in humanized mice, sera taken from 
four mice (7 dpi) were incubated separately with C6/36 mosquito cells and 
amplified for three rounds. Serum from non-infected humanized mice was 
used as negative control and stock NGC virus was used as positive control. 
Before amplification viremia was detected in the sera of two of the four 
infected mice. After the first round of amplification of the samples, DENV 
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was detected by qRT-PCR in the culture supernatants of three out of four 
samples (Figure 3.8).  
 
Figure 3.8 Productive DENV infection in humanized mice (I). Sera of the 
infected humanized mice on 7 dpi were collected, added onto C6/36 cells and 
cultured for 4-5 days (1
st
 amplification). The culture supernatants were used directly 
for assaying viral RNA levels by qRT-PCR. Viral copies per ml of serum or 
supernatant are shown. The dotted line indicates PCR sensitivity level of 100 copies.  
Each of the four samples from virus-infected humanized mice is shown with different 
symbols to track individual mice (see Figure 3.9).   
During the third round of amplification of the same samples, formation of 
syncytium and cytopathic effect became prominent in the cultures (Figure 
3.9A). Furthermore, infectious viruses could be detected in the supernatants 
from these samples by plaque assay (Figure 3.9B) and viral NS1 protein, 
which is produced only during replication, was detected in the infected 
mosquito cells by Western blotting (Figure 3.9C). Similarly, when liver 
homogenates from the infected humanized mice with detectable viremia in 
serum (used above) were incubated separately with C6/36 mosquito cells and 
amplified for three rounds, viral NS1 protein, could again be detected in the 





Figure 3.9 Productive DENV infection in humanized mice (II). Sera (and liver 
homogenates) of the infected humanized mice on 7 dpi  were collected, added onto 
C6/36 cells and cultured for 4-5 days (1
st
 amplification). Cultured supernatants from 
the first round of amplification were concentrated and amplified two more times in 
C6/36 cell cultures. (A) Representative cell culture pictures of C6/36 cells cultured 





rounds. As controls, C3/36 cells were cultured with NGC virus stock from tissue 
culture (10
4
 pfu) or serum from one uninfected humanized mice. (B)  Two culture 
supernatants from the third amplification were used in plaque assay to detect the 
presence of infectious viruses. Shown is a photograph of plaque assay plate. The 
numbers indicate dilution of culture supernatants used in plaque assay. (C) Cells 
incubated with sera and liver homogenates from the third amplification were lysed 
and the presence of viral NS1 protein was detected by Western blotting. Each sample 
from virus-infected humanized mice is shown with a different symbol so as to track 
individual mice from Figure 3.8. 
In addition, liver cryo-sections of one of the infected mice with detectable 
viremia in serum from above were stained with antibody specific for dengue E 
protein. Positive stains were observed only in the sections from infected 
mouse compared to the uninfected negative control (Figure 3.10). Considering 
67 
 
that injected viruses were not detectable 3 dpi in the plain NSG mice, these 
results show that productive infection or production of new viruses take place 
following injection of NGC virus into humanized mice.  
 
Figure 3.10. Detection of viral particles in liver cryo sections of infected 
humanized mouse. Liver sections from one of the infected humanized mouse (left) 
and uninfected mouse (right) were stained with anti-viral E protein (green) and DAPI 
(blue). Representative IF stains are shown (scale bar 500m). A higher amplification 





3.4 DISEASE PATHOLOGY IN THE INFECTED HUMANIZED MICE 
Some of the characteristic clinical symptoms or parameters for identifying 
dengue infection in patients were observed in the dengue infected humanized 
mice.  
3.4.1 DENV infection causes human thrombocytopenia in the infected 
mice 
To determine if thrombocytopenia (or decrease of platelets), an important 
clinical parameter, occurred in the infected humanized mice, blood was 
collected from humanized mice before and on 1, 3, 7 and 10 dpi and stained 
for hCD41 and mCD41. To quantify the numbers of platelets, a known 
number of fluorescent beads was added to each stained blood sample and 
analysed by flow cytometry. As shown in Figure 3.11A human and mouse 
platelets were specifically identified by hCD41 and mCD41, respectively.  The 
percentages of human platelets dropped from 0.37% before infection to 0.03% 
7 dpi (10 fold) in the same mouse. Correspondingly, the count of human 
platelets decreased significantly at all four time points (1, 3, 7 and 10 dpi) post 
infection as compared to their counts before infection while the percentages of 
the mouse platelets remained relatively stable (Figure 3.11A).  The observed 
thrombocytopenia was specific for the human platelets as the number of 





Figure 3.11. Thrombocytopenia of human platelets in the blood of dengue 
infected humanized mice. Significant decrease in human but not mouse platelets in 
the blood of the infected humanized mice. 10l of whole blood from humanized mice 
before and on 1, 3, 7 and 10 dpi were stained with hCD41 and mCD41 and counted 
by flow cytometry using fluorescent beads.  Representative hCD41 versus mCD41 
staining profile of whole blood of a humanized mouse before, 3 and 7 dpi are shown 
(A). The numbers indicate percentages of cells in the gated regions. The average 
counts (± SEM) of human (B) and mouse (C) platelets per microliter of blood of 
humanized mice (n=15) before and at different dpi. *p < 0.05, ** p < 0.01, 
***p<0.001, n.s – not significant.  
3.4.2 Liver damage 
Liver damage is another clinical parameter used for diagnosing dengue 
infection which is measured by the levels of liver transaminases ALT and 
AST. A significant increase in the liver transaminases in the serum of the 
infected humanized mice was seen at 7dpi (Figure 3.12A), which suggests that 
the liver damage occurred during the process of infection. To see if there was 
any infiltration of immune cells, which could be a cause of liver damage, cryo-
sections of the liver from infected mice were stained with hematoxylin and 
eosin (H&E). Cryo-sections of the liver of an uninfected humanized mouse 
served as control. There was mild infiltration in the liver of infected mice 
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compared to the control (Figure 3.12B; left). Further analysis of the liver of 
infected mice showed that there was grouping of cells at various places which 
was not seen in the sections of the control mouse (Figure 3.12B; right). These 
cells were found to be hCD45 cells (green) surrounding an infected cell (red) 




Figure 3.12 Damage in the liver of the infected humanized mice (A) Increase of 
liver transaminases in the serum of infected humanized mice. The levels of ALT and 
AST in the sera of the infected humanized mice (n=7) at 7 dpi and uninfected 
humanized mice (n=5) were measured. The average levels of ALT (left) and AST 
(right) per microliter of serum is shown. (B&C) Infiltration of immune cells in the 
liver of the infected humanized mice. Liver sections from the infected humanized 
mice (n=3) at 7 dpi and an uninfected humanized mouse were stained with H&E (B) 
or IF stains anti-viral E protein (red), anti-human CD45 (green) and DAPI (blue). 
Representative pictures of the liver sections from one infected and uninfected 
humanized mice are shown in B. Representative IF pictures of the liver sections from 





3.4.3 No plasma leakage in infected humanized mice 
Since haematocrit values increase in dengue patients during haemorrhage or 
plasma leakage (which are symptoms of severe infection), they were measured 
in the infected humanized mice. Serum of the infected humanized mice was 
measured before infection and at various time points after infection. There was 
more a decrease than an increase of haematocrit values after infection (Figure 
3.13). This suggests that there was no evident plasma leakage or haemorrhage 
in the system. 
 
Figure 3.13 No increase in hematocrit values in the blood of the infected 
humanized mice. Shown are the hematocrit values of the mice before and after 
infection which are plotted over dpi, Each round dot represents the hematocrit value 
before infection in a single mouse which is connected by a connecting line to the 
square dot, representing its value after infection on the indicated dpi (shown on the x 
axis). There is a downward trend in the lines, which suggests that there was no 





3.5 IMMUNE RESPONSE FROM HUMAN CELLS  
3.5.1 Immunophenotyping of infected humanized mice 
To check the response of human immune cells to the dengue infection in the 












monocytes or macrophages and CD56
+
 NK cells in various organs, such as 
blood, liver, spleen, LN and BM were made at the peak of infection (7 dpi). 
There was no significant change in the percentages of human CD3
+
 T, and 
CD56
+
 NK cells in the blood, liver, spleen, LN and BM (Figure 3.14 A,B,C) 
of the infected mice when compared with the uninfected control, except for a 
decrease in the percentage of CD19
+
 B cells in the blood. The percentages of 
B cells in other organs did not change significantly. There was also an increase 
in the percentage of hCD14
+
 monocytes in the blood while it reduced 












Figure 3.14. Characterization of human cell reconstitution in infected 
humanized mice. Single cell suspensions were prepared from the indicated tissues of 
the infected humanized mice on 7 dpi, stained for various combinations of cell 
surface markers and analyzed by flow cytometry. (A) Representative hCD45 versus 
mCD45 staining profiles of blood, spleen, LN, BM and liver gating on live cells 





among total mononuclear cells. (B) Representative staining profiles for hCD14 versus 
hCD45, hCD19 versus hCD45, hCD56 versus hCD3, and hCD8 versus hCD4 gating 
on hCD45
+
 cells in various tissues. The numbers indicate percentages of positive cells 





), B cells (CD19
+
), T cells (CD3
+
), CD8 T cells (CD8
+
), and CD4 T cells 
(CD4
+
) in various tissues. Human leukocyte chimerism is also shown for each tissue 
(n=10-15). Significance is when compared to the values of uninfected humanized 
mice in Figure 3.2C, which are age and fetal liver HSPCs matched. (D) Reduction of 
the CD4 to CD8 human T cells ratio in the BM. Single cell suspensions from the BM 






 and analyzed by flow cytometry. Shown 
are representative hCD4 versus hCD8 staining profile of hCD3
+
 T cells (left) and the 
ratio (mean +/- SEM) of CD4
+
 cells to CD8
+
 cells of 7 infected mice and 5 uninfected 
mice (right). The numbers in the plots show the percentages of cells in the gated 
regions. Error bars are SEM. *p < 0.05 
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3.5.2 Transient leukopenia of human immune cells in infected mice 
Transient leukopenia is a common feature not only seen generally in viral 
infections but specifically in dengue also (Wilm et al. 2012;Low et al. 2011).  
One consistent observation was a transient decrease in the percentages of 
human CD45
+
 cells in the blood of the infected humanized mice on 1 and 3 
dpi (Figure 3.15). This was not seen in the blood of uninfected humanized 
mice and humanized mice injected with heat inactivated virus. 
 
Figure 3.15 Transient leukopenia of human cells in the blood of the infected 
humanized mice. PBMC were obtained from humanized mice uninfected (n=15), 
infected with live NGC virus (n=15) or injected with heat-inactivated virus (n=5) 
before infection and at 1, 3 and 7 dpi. They were stained for hCD45 and mCD45 and 
analysed by flow cytometry. The percentage of hCD45
+
 cells of each mouse at 
various dpi was normalized to the percentage of the same mouse before infection. 
The averages and SEM are plotted over time. ***p<0.001  
3.5.3 hCD14+ monocytes recruited from the BM to the blood of infected 
humanized mice. 
Following the observation that the levels of hCD14
+
 monocytes increased in 
the blood during the peak of infection at 7 dpi, their numbers where counted at 
the same time point. There was a significant increase in the number of hCD14
+
 
monocytes on 7 dpi (Figure 3.16A). Noting that on the same time point there 
was a decrease in the levels of hCD14
+
 monocytes in the BM, there is the 
possibility that they were recruited from the BM to the blood as a response to 
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infection. Further analysis during the entire course of infection showed that the 
increase in the percentage of hCD14
+
 monocytes in the blood was detected as 
early as 1 dpi and lasted until 20 dpi (Figure 3.16B). Uninfected humanized 
mice and humanized mice injected with heat inactivated virus which served as 
controls did not show any increase in the percentages of hCD14
+
 monocytes in 
the blood on 1 and 3 dpi. This suggests that the increase in the level of 
hCD14
+
 monocytes in the blood is most likely due to the response to the 
infection. 
 
Figure 3.16 Increase in hCD14
+
 monocyte numbers in the blood of infected mice. 
(A) The number of hCD14
+
 monocytes per ml of blood was quantified at 7 dpi by 
multiplying the percentages of hCD14
+
 cells with the total mononuclear cells which 
was counted earlier using hemocytometer. Shown are comparison of the number of 
hCD14
+
 cells before and 7 dpi in the same group of humanized mice (n=13). (D) 
Increase in percentages of hCD14+ monocyte in the blood of infected mice during the 
course of infection. Humanized mice uninfected (Contrl) (n=20), infected with liver 
NGC virus (n=10-15) or injected with heat-inactivated (HI) virus (n=5) were bled, 
PBMCs stained for hCD14 and hCD45 and analyzed by flow cytometry before and at 
the indicated dpi. The percentage of hCD14
+
 cells of each mouse at various dpi was 
normalized to the percentage of the same mouse before infection. Shown are the 
averages and SEM over time. *p < 0.05, ** p < 0.01, ***p<0.001 
3.5.4 Detection of dengue IgM and IgG antibodies 
The presence of dengue specific IgM and IgG antibodies were analysed in the 
serum of the infected mice at various time points, starting from 1 dpi until 84 
dpi. Dengue specific IgM was detected in only 5 out of 29 infected mice at 
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time points 3, 42 and 84 dpi respectively (Figure 3.17) and none of the mice 
detected positive for dengue specific IgG. Out of the 5 mice only one at 42 dpi 
had detectable viremia in the serum. This suggests that there was no strong 
dengue specific antibody response in the infected mice, which might explain 
the lack of rapid clearance of the virus. Therefore this could be a reason for the 
persistence of infection up to a month in the infected humanized mice. 
  
Figure 3.17. Presence of dengue specific IgM antibody in the serum of 5 out of 29 
DENV infected mice. Dengue specific IgM and IgG were quantified in the serum of 
the infected humanized mice at the indicated dpi. Each cross represents the presence 
or the absence of dengue specific IgM in the serum of one infected humanized mouse. 
This plot shows only 5 out of 29 mice were positive for dengue specific IgM 
antibody. Dengue specific IgG could not be detected in the infected humanized mice 
at all dpi. 
3.6 VALIDATING INFECTION OF THE HUMANIZED MICE USING 
A CLINICAL DENV STRAIN 
NGC was isolated over two decades ago and is a lab adapted dengue strain. 
Therefore to validate DENV infection of humanized mice with a clinical 
strain, EDEN DENV2 (07K2861), which was isolated in 2008 from a patient 
with dengue fever and had been passaged only twice since isolation was used 
for infection. Humanized mice were injected with 1x10
7
 pfu of DENV2 
(07K2861) or NGC virus i.v and analysed for virus levels in various tissues on 
7 dpi. Human platelet counts before infection and at 1, 3, 7 dpi were also 
measured. In DENV2 (07K2861) virus infected humanized mice, higher 
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numbers of liver and spleen samples were positive for viral RNA and the level 
of viral RNA tended to be higher as compared to NGC virus-infected mice, 
(Figure 3.18A). Notably, among the five DENV2 (07K2861) virus-infected 
mice, although viremia was detected only in three mice, viral load was 
detected in all five liver samples and four of the five spleen samples. 
However, though platelet drop observed in both the groups, it was not 
statistically different between the groups (Figure 3.18B). 
 
Figure 3.18. Comparison of infection of humanized mice between clinical 
(07K2861) and lab adapted (NGC) strains. (A) Humanized mice (5 per group) 
were injected with 1x10
7
 pfu of 07K2861 or NGC virus. Seven dpi, viral RNA was 
measured in serum, spleen and liver. Shown are viral copies per ml of serum or per 
mg of spleen or liver.  Each symbol represents serum or tissue from one mouse. The 
dotted lines indicate the sensitivity of PCR at 100 copies. The numbers in the 
parentheses indicate the number of mice where viral copies were below the detection 
limit. (B) 10l of whole blood from humanized mice infected with NGC or 07K2861 
before and 1, 3 and 7dpi and platelets counted by flow cytometry. As control, 
uninfected humanized mice were also bled at the same time points. The count of the 
human platelet of each mouse at various dpi was normalized to the count of the same 
mouse before infection. Shown are the averages and SEM are plotted over time.  
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3.7 COMPARISION OF ANIMAL MODELS OF DENGUE INFECTION 
WITH THE MODEL IN THIS STUDY  
Several animal models for dengue infection have been reported in literature. A 
comparison of the dengue infection in the humanized NSG mouse 
(Kalayanarooj et al. 1997;Mota and Rico-Hesse 2011;Mota and Rico-Hesse 
2009) and non-human primate model (Jaiswal et al. 2009) with the humanized 
NSG mouse model developed in this study is given below in table 3.2 and 
table 3.3 





























Human fetal liver 
Age of NSG mice at 




3 month old 
adults 
New born pups 
Route of 
reconstitution 
Intra-hepatic Intra-venous Intra-cardiac 
Presence of human 




Virus Clinical strains NGC 
NGC & clinical 
strain 














% mice in which 
viremia was detected 
in serum 
100% 82% 46% 















No of days viremia 
detected in serum 




Present till 26 dpi 
(analyzed till 26 
dpi) 
Present till week 9 
(analyzed till week 
12) 
Detection of viral 
load in organs 
Spleen, BM 
(not in liver) 
Liver, spleen, BM 




Rash and fever 
Rash (30% mice) 
(data not shown) 
ND 
Liver damage ND ND 
Increase in serum 
ALT and AST 
levels at 7dpi 
Thrombocytopenia 
Significant 





Significant  drop at 
many dpi 
(Human platelets) 






of T cells in 
bone marrow 
T cell responses: 






- CD14+ cells 
increase in blood 
- IFN (22% 
infected mice) 
- Decrease in 
CD4/CD8 ratio in 
bone marrow 
Antibodyresponse No IgM/ IgG 
IgM (50-70% of 
infected mice) 












Table 3.3 Comparison with non-human primate model of dengue 
PARAMETERS 
NHP model 




(Virus grown in vero cells) 
DENV2 (NGC) 
(Virus grown in mosquito 
cells) 




 PFU, i.v 10
7
 PFU, i.v 









Peak and duration of 
infection 
Peak by 3-4dpi 
Present till 14 dpi 
Peak at 7dpi 
Present till week 9 
(analyzed till week 12) 
Petechiae and rash Present Absent 
Fever, inappetence or 
lethargy 
Absent Absent 
Liver damage Increase in ALT/AST at 7dpi 
Increase in ALT/AST at 
7dpi 
Hematocrit No increase (Decreased) No increase (Decreased) 
Thrombocytopenia 




Significant drop in 
human platelets 
Transient leukopenia in 
blood 
Present during till 10 dpi 




(nadir at 1and 3dpi) 
Antibody response 
Dengue specific IgG and 
IgM generated 
IgM (23% infected 





3.8 DISCUSSION & CONCLUSION 
In this study, I have constructed humanized NSG mice with human CD34
+ 
cells having significant levels of human platelets, hepatocytes, 
monocytes/macrophages and other immune cells.  This small animal model is 
a good platform to study the dengue disease pathogenesis, as the wild type 
DENV can only infect humans. Injection of both lab-adapted and clinical 
strains of DENV2 virus led to a systemic infection with characteristic 
symptoms including transient leukopenia, elevation of blood monocyte levels, 
thrombocytopenia and liver damage.  
Sub-lethally irradiated NSG mice were injected with fetal liver HSPCs that are 
CD34
+
 cells among which around 10-20% are also CD133
+
 suggesting they 
contain both the lineage committed (CD34
+





) progenitors, where the latter has the potential to give long 
term repopulation of T, B, myelomonocytic and megakaryocytic cells in vivo 
(Jaiswal et al. 2009). The presence of committed lineage cells is also important 
so that they can provide initial support to the developing cells. Among the rest 




 cells that have been shown 
to give rise to hepatocyte-like cells and perceived to be hepatocyte progenitors 
(Yin et al. 1997). Thus due to the presence of all the three populations, the 
entire human immune system develop with cells from the lymphoid lineage 
and myeloid lineage and reconstitute in various mouse organs along with 
human hepatocytes in the liver. However, it should be noted that these mice 
still have the inherent drawbacks as detailed in section 1.4.3. Significant levels 
of human platelets were also detected in these mice whereas the previous 
studies of DENV infection in humanized mice did not report the presence of 
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human platelets. It has been observed that in fetuses and neonates, the fetal 
liver accounts for up to 95% of thrombopoietin (TPO) production (Chen et al. 
2013), which is the principal regulator that drives the differentiation and 
maturation of megakaryocytes, the progenitor to platelets (Wolber et al. 1999). 
It is likely that production of hTPO by human hepatocytes, along with the 





leads to a higher level of human platelets in mice reconstituted with human 
fetal liver CD34
+ 
cells. The presence of human platelets along with human 
immune cells makes our humanized mouse model a suitable platform to 
understand the dengue disease pathogenesis, such as thrombocytopenia, which 
is covered in the next chapter. 
I have successfully established a humanized mouse model for dengue infection 
by injecting the DENV2 NGC virus intra-venuously and therefore re-creating 
several of the blood borne host-viral interactions observed in dengue disease. 
The NGC strain used in this model replicates efficiently in human cells but not 
in mouse cells. Thus, when injected into the NSG mouse with a human 
immune system, the DENV was able to specifically infect and replicate in the 
human cells. The s.c route of infection though being the natural route of 
infection for DENV did not result in detectable viremia in the serum in this 
model. A possible reason for this could be the absence of human target cells, 
such as Langerhans or DCs (Kaushansky 2006) under the skin of the 
humanized NSG mice (Wu et al. 2000). Due to the deficiency of these cells, 
the virus, which could infect only human cells, could not replicate and reach 
the blood system where it could have been detected in the serum. However, 
the increase in hCD14
+
 monocytes in the mice injected with the virus suggests 
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that there was a response to the injected virus. When the DENV was injected 
i.v into the blood, where there was enough target cells for the virus to 
replicate, leading to a systemic infection.  
Using PCR viremia could be detected in serum until 28 dpi and virus was 
detected in major organs such as liver, spleen, LNs and even the BM. 
However, since the mice had relatively low viral levels, the mice had to be 
euthanized at each time point to assess viremia (so that enough serum could be 
obtained such that the viral copies in the sample were at least 100 copies). And 
due to the same reason, plaque assay was not sensitive either. Also, as 
mentioned in the results section, there might be a slight over estimation of the 
viral load in highly vascularized organs such as the liver and spleen due to the 
presence of viruses in the blood. The presence of infectious viral particles in 
serum and liver homogenates was confirmed by culturing them in C6/36 cells, 
where there was a 2 log increase in viral load in the supernatants after 
passaging in mosquito cells. Also, detection of viral particles even in the 
serum of the mice with undetectable viremia, after culture with mosquito cells, 
suggests that all the mice were indeed infected. Probably, the viremia levels 
were lower than the sensitivity of PCR which was around 100 copies per 
reaction, because of which, it was not detected. The usage of antibodies 
against the non-structural proteins could have helped to directly confirm 
productive infection in this model and exclude the possibility that the observed 
viral copies might be from the high number of input viruses. Nevertheless, the 
initial disappearance of virus in the blood, followed by a 5 log increase at 
7dpi, viral particles not being detected in the organs of non-humanized NSG 
mice from 3dpi and isolation of infectious viral particles from the serum at 
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7dpi, points towards a possibility of productive infection in these infected 
mice. Infecting the model with a clinical isolate DENV2 (07K2861) virus has 
shown that this model can be infected with a non-culture adapted virus 
recently isolated from a dengue patient.  
In this model, depletion of platelets, transient leukopenia and increase in liver 
transaminases (ALT or AST), a symptom of liver damage was also seen. 
Thrombocytopenia, specifically of human platelets was the key observation in 
this model. Interestingly, thrombocytopenia was observed in humanized mice 
even with viremia levels below the detection limit which is discussed in the 
next chapter. This raises the possibility that thrombocytopenia could be used 
as a more sensitive and convenient marker for monitoring infection during 
testing of potential therapeutics compared to viremia, as only 10l of blood is 
needed for the assay. Transient leukopenia, a common feature not only seen in 
viral infections but specifically in dengue patients also (Lockridge et al. 
2011;Low et al. 2011), was also observed in this model. There was also a 
decrease in the frequency of B cells in the blood observed at 7dpi in the mice. 
There is evidence from the other model of dengue in humanized NSG mice 
(Kalayanarooj et al. 1997), that there was a decrease in dengue positive B cells 
in blood of the humanized mice. Though, this was not specifically checked, 
this may contribute to both the leukopenia and decrease in B cells observed in 
the infected mice.  The liver damage during dengue disease is believed to be 
caused by the infiltration of immune cells (Mota and Rico-Hesse 2011), which 
was also observed in this model. There were also elevated levels of monocytes 
in the blood as observed in humans (Sung et al. 2012). Significant reduction of 
CD4 to CD8 ratio in human T cells was also seen in the BM as a result of 
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infection, which is seen in the blood of some of the patients in severe phase 
(Tsai et al. 2011). Thus, the humanized mouse model of dengue infection 
reported here captures some key features of dengue infection.   
DENV causes an acute infection in humans and viremia is normally gone in 
less than a week. The much longer period of viremia in the humanized mice is 
likely because of the poor B-cell responses as indicated by the lack of 
significant levels of dengue-specific antibody responses in infected mice. 
Also, haemorrhage and plasma leakage were not observed. As discussed in the 
introduction, plasma leakage, which is one of the severe manifestations, is 
thought to occur because of micro vascular dysfunction due to exposure to 
inflammatory mediators on the endothelial wall (Liu et al. 2002). There is also 
a report on direct infection of endothelial cells by DENV which in turn 
secretes cytokines like IL-6, IL-8 and RANTES (Basu and Chaturvedi 2008). 
This complex interaction between the virus, endothelial cells and host immune 
response increases vascular permeability and might result in plasma leakage 
(Huang et al. 2000). In the other mouse models of dengue where plasma 
leakage was observed (Srikiatkhachorn 2009), the combination of infected 
mouse cells and mouse immune cells may allow the plasma leakage to occur. 
In the humanized mouse model, however, this interaction between the human 
immune cells and mouse endothelial cells might be very limited, thus resulting 
in no leakage. It is also evident from this model, that the presence of viral 
load, including viremia, is not sufficient for the mice (and by inference 
humans) to develop a severe disease. This implies that host responses rather 
than viral factors, might play a crucial role in development of severe disease.   
86 
 
Similar to the previously reported DENV infection in humanized NSG mice in 
table 3.1 (Tan et al. 2010) (Mota and Rico-Hesse 2011;Mota and Rico-Hesse 
2009), there was a systemic DENV infection in this model with comparable 
viral levelss, poor induction of dengue specific antibody response along with 
infiltration of T cells in the BM. However, engraftment of NSG mice with 
human fetal liver CD34
+
 cells is the key difference between this and previous 
studies (where engraftment was done with human cord blood CD34
+
 cells) and 
this resulted in the generation of human hepatocytes in the mouse liver which 
in turn might have helped in the development of platelets. This major 
advantage in this model leads to the induction of thrombocytopenia in infected 
mice which is specific to human platelets despite the presence of numerous 
mouse platelets. This is in contrast to a drop of total platelets in infected 
humanized mice reported by Mota and Rico-Hesse while Jaiswal et al did not 
observe any change in platelets even though the same strain of DENV was 
used. Also, infected cells could be detected in the liver in this model, which 
probably are human hepatocytes (data not shown) while Mota et al could not 
detected any infected cells in the mouse liver. Another difference is that there 
was transient leukopenia and liver damage observed in the model in this thesis 
while it was not measured in the other models. Mota et al reported the 
presence of rash which was absent in the model described here. The 
differences could be attributed to engraftment of fetal HSPCs, strain of virus 
and dose/route of inoculation used. Thus, the humanized mouse model of 
DENV infection described in this tehsis not only shares many common 
features but also has some unique advantages. 
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 Interestingly, when comparing to the non-human primate model (table 3.2) 
(Jaiswal et al. 2009), a number of similarities were observed. With the 
exception of the strain of virus used, the dose and route of inoculation was 
same in both the models (1x10
7
 pfu, i.v.). There was increase in liver 
transaminases such as ALT/AST at 7 dpi, no increase in hematocrit values, 
thrombocytopenia and transient leukopenia in both the models. Though there 
were no signs of sickness observed in both the models, petechiae and rash was 
specifically observed in the NHP model. A probable explanation of the 
difference could be due to the reaction of the primate endothelial cells to the 
inflammation of the primate immune cells in them, in contrast to the model in 
this thesis. However, the absence of plasma leakage (no increase in hematocrit 
value) might be because of the absence of a full repertoire of immune 
response. Another key difference observed was the clearance of viremia in the 
NHP model caused by a strong dengue specific antibody response, both of 
which was absent in the model in described in this thesis. This again could be 
attributed to the drawbacks of the humanized NSG mouse model where 
inherently there is poor humoral response.  However, the primates did not 
appear sick suggesting that fever and other symptoms of sickness such as 
lethargy may not be related to the presence of dengue specific antibodies. 
Thus dengue infection in the humanized NSG mice has been successfully 
established with both lab-adapted and clinical strains and the immune response 
from human cells could be characterised. However, there are limitations of the 
model such as absence of severe disease, non-clearance of viremia and 
absence of a strong humoral response as observed in patients, which is due to 
the inherent drawbacks of the humanized NSG mouse such as poor antibody 
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production ability, abnormalities in the T cells, absence of complement 
factors, absence of human endothelial cells, etc. Also the disease pathogenesis 
that involves non-immune cell types that are not of human origin such as 
plasma leakage cannot be studied either. Nevertheless, at present no animal 
model for dengue can fully exhibit all the clinical symptoms and immune 
response as it occurs in humans. Each animal model has its own unique 
advantages that can help in the study of one or few aspects of the dengue 
disease pathogenesis or therapeutics. The knowledge from all these models 
needs to be pooled in other to fully understand the dengue disease. Similarly, 
the advantage of the model described in this thesis is that the pathogenesis of 
the disease can be studied in a human cell context and the model has been 











CHAPTER 4: INHIBITION OF MEGAKARYOCYTE AND 
THEIR PROGENITOR CELL DEVELOPMENT IN THE 
BONE MARROW UNDERLIES DENV-INDUCED 





Platelets are anucleated, discoid cells of size 2–3 μm. They play a major role 
in haemostasis and coagulation, the loss of which can result in bleeding. The 
platelet count in normal healthy humans ranges from 150,000 to 450,000 per 
l of blood (Onlamoon et al. 2010). Platelets are derived from megakaryocytes 
(MK), which are large, nucleated (usually polyploid) of size 30-100 m. MK 
arise from pluripotent HSPC in the BM (Daly 2011); (Thon and Italiano 
2012), especially from megakaryocytic colony forming units (CFU-MK) 
which can be identified by the co-staining of CD34 and CD41 (GP IIb, IIIa) 
(Avecilla et al. 2004).  TPO is the principal regulator that drives the 
expansion, differentiation and maturation of the progenitors to MK (Tomer 
2004); (Kaushansky 2006). It is mainly produced by liver and to some extent 
the kidneys (Avecilla et al. 2004). The mechanism behind the development of 
platelets from MK is still under debate. The most commonly accepted 
hypothesis is that upon maturation the MKs travel to the vascular niche in the 
BM and form long branching processes called proplatelets, which later release 
platelets from their tips (Wolber and Jelkmann 2002;Italiano et al. 2008). One 
MK can give rise to 1000–3000 platelets (Italiano et al. 2007). 
 Thrombocytopenia or loss of platelets occurs when the levels of platelets fall 
dangerously below 50,000 per l of blood. It has been routinely used as a 
predictive and distinguishing marker for dengue disease from other viral 
infections such as Chikungunya (Stenberg and Levin 1989). Evidences 
suggests that thrombocytopenia might also contribute to haemorrhage or 
bleeding during dengue disease though this is not entirely conclusive (Lee et 
al. 2012;Krishnamurti et al. 2001). At present, there is no other treatment to 
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specifically control thrombocytopenia during the dengue disease in patients 
other than prophylactic platelet transfusions, (use of which is still under 
controversy).  Even after decades of research in dengue infection, the 
mechanisms behind thrombocytopenia have not been clearly elucidated in 
vivo.  
Two hypotheses have been proposed to explain thrombocytopenia during 
dengue infection – clearance of platelets from periphery or loss of platelet 
production in the BM. Clearance of platelets from the periphery could be 
antibody-mediated.  One possibility is that antibody-opsonized DENV bind to 
platelets, which are then cleared by activated immune cells (W. W. Duke 
1910). Others suggest that antibodies to the viral protein NS1 cross react with 
auto-antigens expressed on platelets and binding of such cross reactive 
antibodies tags the platelets for clearance (Wang et al. 1995). Alternatively, 
platelet production in the BM could be inhibited or suppressed, although the 
evidence supporting this hypothesis is lacking due to difficulties in obtaining 
BM biopsies from acute dengue patients. However, there is a single report that 
observed the BM to be hypo-cellular when the biopsies were taken from 
patients earlier in the dengue disease phase but later became hyper-cellular (as 
if recovered from acute suppression) (Lin et al. 2001). Support is also 
provided by the NHP model of dengue infection, which has shown some 
evidence of direct infection in the BM (Nelson et al. 1964). Experiments done 
in an artificial model of BM, in vitro, show that the BM could be infected, 
reducing its ability to support haematopoiesis, including the production of 
MKs (Noisakran et al. 2012). However, the cause of thrombocytopenia during 
dengue infection is still unclear.  
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As it is very difficult to perform such studies in patients, the humanized mouse 
model for dengue can be used to understand the mechanism behind 
thrombocytopenia. Though there are reports of dengue infection in the 
humanised NSG mouse (La Russa and Innis 1995), (Mota and Rico-Hesse 
2011), neither of these groups reported the presence of human platelets in their 
model. Hence specific studies to understand the mechanisms of 
thrombocytopenia during the disease pathogenesis have not been conducted. 
As human specific thrombocytopenia was observed, this humanized mouse 
model for dengue to analyse the factors and events that can lead to 





In the previous chapter, the absence of dengue specific antibodies in the 
infected humanized mice was discussed. Therefore, antibody mediated 
peripheral clearance is unlikely to be a significant cause of human 
thrombocytopenia in the humanized mice. Thus human thrombocytopenia 
could be caused due to loss of platelet production which in turn might be due 
to loss of hTPO production in the liver (potentially because of DENV initiated 
liver damage) or suppression of production of platelet progenitors (due to 
infection in BM). I have thus analysed whether these factors contribute to 
thrombocytopenia in the infected humanized mice. 
4.2.1 Thrombocytopenia as a marker for infection in humanized mice 
As mentioned in the previous chapter thrombocytopenia, specifically of 
human platelets was seen in the infected humanized mice. As there were 
infected mice with detectable and below detectable viremia (Figure 4.1A), 
their respective human platelet counts were plotted and compared to the 
human platelets counts in uninfected mice and mice injected with heat 
inactivated virus (Figure 4.1B). It was found that there was a significant drop 
in the human platelet counts in mice having detectable and below detectable 
viremia in their serum, when compared to the uninfected control. This drop 
was not seen in the mice injected with heat inactivated virus. Thus, 





Figure 4.1 Presence of human thrombocytopenia in infected mice regardless of 
having detectable viremia in blood. (A) Viremia levels at 7 dpi in 25 infected mice 
where 17 mice had detectable viremia in blood while 15 mice had below detectable 
viremia. The mice injected with heat inactivated virus had no viremia in the blood. 
Each dot represents one mouse. The horizontal lines indicate the average viral copies 
in serum collected from mice at the 7 dpi. The dotted lines indicate the sensitivity of 
PCR at 100 copies.  The numbers in the parentheses indicate the number of mice 
where viral copies were below the detection limit. (B) Human platelet counts in the 
uninfected mice (n=25; shown as blue bar), infected mice from panel A with 
detectable viremia (n=17; shown as red bar) and below detectable viremia (n=15; 
shown as orange bar) and mice injected with heat inactivated virus (n=5; shown as 
green bar). Error bar is ± SEM. *** p<0.001 when  compared with uninfected 
controls 
4.2.2 Thrombocytopenia of human platelets induced by dengue infection 
To confirm that thrombocytopenia of human platelets was caused by 
productive infection; humanized mice were injected i.v with NGC virus or 
NGC virus in complex with humanized anti-dengue E protein antibody (4G2) 
to neutralize the virus as described in materials and methods. Human platelet 
counts were quantified before and 7 dpi and the viral loads were measured in 
the blood, spleen and LN 7 dpi. While viral load was detected in the spleen of 
4 out of the 5 mice and in the blood and LN of 3 out of the 5 mice that were 
injected with NGC virus, no virus was detected in any tissue of mice that were 
injected with the virus in complex with antibodies (Figure 4.2A). Consistent 
with the previous observation, a significant drop in human platelets was 
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detected at 7 dpi in all five mice that were injected with NGC virus.  In 
contrast, no significant drop in human platelets was detected in mice that were 
injected with virus in complex with antibodies (Figure 4.2B). Together, these 
data suggest that productive DENV infection in humanized mice induces 
human thrombocytopenia. 
 
Figure 4.2. Thrombocytopenia is induced by dengue infection. Humanized mice (5 per 
group) were injected with NGC virus (1x10
7
 pfu) or a mixture of NGC virus and 
humanized 4G2 antibody. (A) Viral copies were measured in the serum, spleen and LN on 
7 dpi. Each symbol represents serum or tissue of one mouse. The horizontal lines indicate 
the average viral copies in each tissue at the same dpi. The dotted line indicates the 
sensitivity of PCR at 100 copies. The numbers in the parentheses indicate the number of 
mice where viral copies were below the detection limit.(B) Human platelet counts were 






4.2.3 hTPO not involved in thrombocytopenia in infected humanized 
mice 
Production and maturation of human MKs and generation of human platelets 
requires human TPO, which is mainly produced in the liver. There could be a 
loss of hTPO production in the liver due to the damage in the liver induced by 
dengue infection as reported in the previous chapter. Since the hTPO protein 
levels are very low even in humans and it is difficult to measure, the 
expression of hTPO encoding gene was analysed. Total RNA was extracted 
from the liver of infected humanized mice at 7dpi and the expression of hTPO 
was quantified using qRT-PCR. The house keeping gene, hGAPDH was used 
as an internal control. RNA from human fetal liver and non-humanized NSG 
mouse liver was used as positive and negative control, respectively. The 
relative gene expression of hTPO (with respect to GAPDH) in the infected 
humanized mice at 7 dpi was not significantly different from that of the 
control humanized mice (Figure 4.3). Even though there was damage to the 
liver, the hTPO expression levels were not drastically affected and thus, were 






Figure 4.3. Excluding involvement of hTPO in causing human 
thrombocytopenia. Infected humanized mice were sacrificed on 7dpi and total RNA 
was extracted, converted to cDNA and the relative gene expression of hTPO and 
hGAPDH was quantified using qRT-PCR with their respective primers. As controls, 
RNA from human fetal liver (PC) and from non-humanized mouse liver (NSG) was 
used. (A) Agarose gel electrophoresis of the amplicons of qRT-PCR with hGAPDH 
products at 172bp and hTPO products at 80bp. The first lane corresponds to the 
marker (M), the next eight lanes to the amplicons of uninfected humanized mice 
(n=4), the next 12 lanes to the amplicons of infected humanized mice (n=6) and the 
subsequent lanes corresponds to the positive control (PC), negative control (NSG) 
and no template control as indicated. (B) Average 2
cT 
values of the uninfected 
humanized mice (controls; n=4) and infected humanized mice (n=6) showing no 
significant difference between the values. Error bars are SEM. n.s – not significant. 
4.2.4 Decrease of MKs in BM after infection 
Since there was no change hTPO levels after infection, the observed 
thrombocytopenia could be due to inhibition of platelet production in the BM 
of the infected humanized mice. Thus, the frequencies of the platelet precursor 
MKs in the BM of uninfected and infected mice were analysed. Human MKs 
were identified by their large size (high FSC) and expression of hCD41
+
. 




 MKs in uninfected mice, the frequencies 
the same populations were significantly decreased 1, 3, 7 and 10 dpi in the 
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infected mice (Figure 4.4A, B). Thus there was a drop in the frequencies of 
human MK in the BM in the DENV infected in humanized mice. 
 
Figure 4.4. Reduction of human MKs in the BM of infected humanized mice. 
Infected humanized mice were sacrificed at the indicated dpi and single cell 
suspensions were prepared from the BM of the infected humanized mice (n=10-15) at 
various dpi, stained for the marker hCD41 and analyzed by flow cytometry. (A) 
Representative staining profiles for hCD41 versus FSC in BM of the uninfected mice 
and infected mice on various dpi. The numbers indicate percentages of positive cells 
in the gated region. (B) Significant decrease in human MK populations. Average 
percentages of human MKs (CD41
+
) among live cells, in BM of the uninfected mice 
and infected mice on various dpi. *p < 0.05, ** p < 0.01. Error bars are SEM 
 
4.2.5 Cells other than the MKs appear to be infected in the BM  
The infection in the human MK could lead to their reduction in the BM of the 
infected humanized mice. To confirm, positive mice with drop in human 
platelets were selected and human, mouse MK (identified by markers hCD41 
and mCD41 respectively) and the MK negative (MK-) populations were sorted 
out from the BM from both the femurs of the infected mice at early time 





copies per ml of serum (data not shown). The presence 
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mouse MK and 10
6 
MK- cells were sorted from each mouse on the indicated 
dpi (Figure 4.5B). qRT-PCR analysis revealed presence of viral particles in 
the MK- populations of the BM in 2 out of 5 infected humanized mice on 1dpi 
but none on 3 dpi (Figure 4.5C). However, no detectable viral RNA was found 
in both human and mouse MKs from the cells sorted on 1 and 3 dpi. These 





Figure 4.5. Cells other than the MKs may be infected in the BM. Infected humanized 
mice were sacrificed at 1 and 3 dpi and single cell suspensions were prepared from the 2 
femurs of the infected humanized mice (n=5), stained for the markers hCD41 and mCD41 




) and MK- (h/m CD41
-
) populations using 
FACS. (A) Representative staining profiles for hCD41 versus mCD41 in BM of the 
infected mice before sorting and after sorting for hMK, mMK and MK-. The boxes indicate 
the gates used while sorting (B). The average counts of hMK, mMK and MK- populations 
after sorting from the single cell suspensions of the 2 femurs from 1 and 3 dpi infected 
humanized mice. The sorting of MK- population was stopped when 1.3x10
6
 cells were 
collected. Error bars are SEM. (C) Viral levels in 2 femurs measured by qRT-PCR in the 
sorted populations hMK, mMK and MK-. Each symbol on the respective dpi represents one 
mouse. The dotted lines indicate the sensitivity of PCR at 100 copies.  The numbers in the 
parentheses indicate the number of mice where viral copies were below the detection limit. 
4.2.6 Depletion of human MK precursors in the BM of infected mice 
Since viral particles were found in the MK- populations, the infection probably had 
an effect on the human megakaryocytopoiesis, thus leading to thrombocytopenia. 
To verify this hypothesis, human hematopoietic progenitor cells of the BM cells 
were analysed by staining for CD45, CD34 and CD41 in the infected humanized 





progenitor cells in the BM remained similar before and after 
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 cells, which are known 
to give rise to CFU-MK, decreased significantly 1, 3, 7 and 10 dpi (Figure 4.6 A, B, 
C). Together these data suggest that the dengue infection-induced thrombocytopenia 
is associated with a specific depletion of human MKs and their progenitors in the 
BM. 
 
Figure 4.6. Depletion of human MK precursors in the BM of the infected mice (A) 
Representative staining profiles for hCD34 versus hCD45 and hCD34 versus hCD41 in 
BM of the uninfected and infected mice at various dpi is shown. The numbers indicate 
percentages of positive cells in the gated region. (B) No change in the average values of 
human progenitor cells (CD34+CD45
low





) among live cells in BM of the uninfected and infected mice on 









) in BM of the 
uninfected and infected mice on various dpi. Error bars are SEM. *p < 0.05, ** p<0.01, 







4.3 DISCUSSION AND CONCLUSION 
One important observation in this model was that productive dengue infection 
also induced human specific thrombocytopenia in the blood of the infected 
humanized mice. This was not reported previously in other models of dengue 
disease. This feature made it possible to use the humanized mouse model for 
dengue to understand thrombocytopenia during dengue disease. Though 
thrombocytopenia has been used as a predictive marker for dengue, the cause 
or mechanisms leading to thrombocytopenia are still unclear. I have shown 
that depletion of human platelets is not due to antibody-mediated clearance or 
a lack of human TPO, but to a specific inhibition of production of human MKs 
and their progenitor cells in the BM.  
Although the involvement of the BM has been suggested nearly five decades 
ago, until recently, the focus has primarily been on the mechanisms behind 
peripheral clearance mediated by dengue specific or cross reacting antibodies, 
which mark the platelets for clearance. However, this requires an acute 
antibody response against the virus. Thus, antibody-mediated depletion can ne 
excluded as a significant contributing factor to thrombocytopenia because 
none of the infected mice produced dengue-specific IgG and most of the mice 
did not produce detectable levels of dengue-specific IgM, consistent with our 
previous report of poor antibody induction in the humanized mice (Jaiswal et 
al. 2009) . Since plasma leakage was not detected in the infected mice, the loss 
of platelets due to the plasma leakage can also be excluded. However, 
evidence of alterations in megakaryocytopoiesis was found in the BM due to 





progenitor cells in the BM as the major cause of thrombocytopenia in 
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humanized mice. Following infection, a significant drop in the level of MKs 





 progenitor cells that give rise to MKs. The depletion of 
MKs and their progenitor cells in the BM is not due to a lack of hTPO in 
infected mice as it is critical for MK and progenitor cell differentiation. TPO is 
normally produced by hepatocytes in the liver.  I showed that the level of 
hTPO transcript remained detectable and did not change before and after 
infection. Also, viral RNA was not found in the purified human MKs, 
suggesting that direct infection of MKs may not be a major cause of their 
depletion in this model, though further work is required to confirm this. In an 
in-going work in our lab, there is some evidence suggesting a strong negative 
correlation between apoptosis markers (such as BCL2) with platelet counts in 
the blood of DENV infected patients. Thus, it is likely that the infection in the 
BM alters its microenvironment, which reduces the human MK progenitors 
(probably both by apoptosis and suppression megakaryocytopoiesis) in the 
bone marrow, coinciding with human thrombocytopenia in the periphery.  
Our study has shown that the DENV infection of BM can have an implication 
in causing thrombocytopenia in the blood in the absence of antibody mediated 
peripheral clearance. It was also clearly demonstrated that when the virus is 
neutralized, thrombocytopenia of human platelets was not observed in the 
blood of the humanized mice, suggesting that the human thrombocytopenia 
was induced by DENV infection. Thus, this study has elucidated the 
mechanisms underlying thrombocytopenia in humanized mice and this 
mechanism might be applicable to dengue-induced thrombocytopenia in 
humans. This model could also be used for therapeutic investigation using 
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platelet drop as a practical approach to follow dengue infection in the 












CHAPTER 5: SINGLE NUCLEOTIDE VARIATION IN THE DENGUE 





5.1  BACKGROUND 
RNA polymerases unlike DNA polymerases lack the proof reading 
mechanisms to maintain the fidelity of the genome and hence are highly error 
prone. Thus, the mutation rates of RNA viruses (such as influenza and retro 
viruses) are extremely high, resulting in quick adaptation and rapid evolution 
(Chen et al. 2012). However, in the case of flaviviruses, the error rate is 
relatively lower and they have greater fidelity (Domingo et al. 1996) which 
explains their highly conserved regions. Despite their mutation rate, a single 
mutation in any of the translated or untranslated regions can have a major 
impact on the replication and virulence of the virus and this concept has also 
been applied to design vaccines for dengue (Pugachev et al. 2004).  
Recent studies in coding regions such as NS4B (Durbin et al. 2001) (Grant et 
al. 2011), NS2A (Leitmeyer et al. 1999) (Steel et al. 2010), NS4A (Bennett et 
al. 2003) and NS5 (Steel et al. 2010) have shown that mutations (substitutions 
and deletions) have the potential to both increase the virulence or attenuate 
DENV. The amino acid Valine at position 751 (corresponding to nucleotide A 
at position 1688) is known to be highly conserved and mutation at this 
position was found to affect the viral replication (approximately by 100-fold) 
in C6/36 mosquito cells line and in Vero cells (Leitmeyer et al. 1999). The 5` 
and the 3` UTR are highly conserved and equally critical as they have an 
implication on the replication of virus by providing signals for negative strand 
synthesis, RNA packaging and stable formation of secondary structures 
(Kroschewski et al. 2009). Mutations can give an altered viremia pattern 
(Wengler and Castle 1986), viral growth restriction (Men et al. 1996) or lead 
to attenuation of the virus (Cahour et al. 1995). The 3` UTR is particularly 
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known to be important for virus growth and replication (Durbin et al. 2001), 
with its first 110 nucleotides being highly conserved (Hahn et al. 1987).  
Mutations generally accumulate when viruses are passaged over a long period 
of time. DENV2 - New Guinea C (NGC) virus was isolated from a dengue 
fever patient in New Guinea in 1944 (Leitmeyer et al. 1999) by numerous 
passaging in the cerebrum of mice. It has been widely used and passaged over 
the decades and is a well-adapted lab strain. There is a high probability that 
the virus has accumulated mutations till date. Mutations can occur 
spontaneously in small populations of the virus within a single host, which are 
known as quasi species. When passaged over several times these quasi-species 
can become significant enough for the mutations to alter the characteristic of 
the virus population as a whole.  
 I acquired DENV2 NGC from two different sources. When these viruses were 
cultured in mosquito cells and used for infecting humanized and non-
humanized mice, significant differences was observed between them. The 
observed differences were both in vitro and in vivo and subsequently found to 
be associated with the frequencies of quasi species having a single nucleotide 
difference between them. Here I describe how the observed mutation altered 









Note: The two strains will be referred as NGC-G and NGC-A where G and A 





strains respectively. Detailed description will be given in section 5.2.2 
5.2.1 Differences between the two viruses in vitro 
To check for the differences between the viruses in vitro, approximately 
1x10
4 
pfu of both the NGCs were used to infect the same batch of C6/36 
mosquito cells. The formation of syncytium (clumping of cells) which is a 
characteristic feature exhibited by the dengue infected mosquito cells C6/36 in 
culture, was at its maximum at 2.5 dpi in the NGC-G infected mosquito cells, 
while showing no apparent cytopathic effect (CPE). However, the formation 
of syncytium reached a maximum at 4.5 dpi in the NGC-A infected mosquito 
cells (Figure 5.1). When their cell culture supernatants were harvested on the 
days 2.5 and 4.5 respectively, concentrated and titrated by plaque assay, a 
difference in the viral titre could be observed, where the tire was 1x10
8
 pfu per 
ml for NGC-G while the titre was 5x10
7
 pfu per ml for NGC-A. These results 
clearly demonstrate that there were variations in the replicating efficacies 
between the two strains and the virus production in NGC-G infected cells was 





Figure 5.1 Differences observed during cell culture of C6/36 when infected with 
NGC-G and NGC-A. A monolayer of C6/36 mosquito cells was infected with 1x10
4
 
pfu NGC-G and NGC-A separately. Shown are the cell culture pictures of C6/36 cells 
taken on 3 dpi after infection with NGC-G (A), NGC-A (B) and uninfected cells (C). 
5.2.2 A major mutation found in the 3`UTR region of the NGC-A strain 
To detect differences in the sequence of their respective genomes, RNA was 
isolated from the NGC-G and NGC-A and the whole genome was sequenced 
using Illumina next generation sequencing (NGS) approaches (Sabin and 
Schlesinger 1945). There was a total of 56 million reads for NGC-G and 47 
million reads for NGC-A. The depth of sequencing coverage for both the 




 reads) with around 97% reads of 
the mapping to the reference, indicating reliable and high quality of reads 
(Figure 5.2). The reference sequence for the complete genome for DENV2 







Figure 5.2 Depth of coverage of NGC-G and NGC-A sequences during NGS. The 
covearge plot of  NGC-G (left) and NGC-A (right) demostrate high depth of coverage 
of both seqeunces during NGS.  
Sequencing revealed a single major nucleotide variation (1 nucleotide 
difference) in the consensus or the master sequence at genomic position 10381 
of NGC-A when compared to NGC-G and the reference sequence (Figure 
5.3A). The reference sequence and NGC-G had the nucleotide G at position 
10381 while it was mutated to A in the NGC-A viral sequence. On further 
analysis, this position in the master sequence was found to correspond to the 
3` UTR of the viral genome (at position 109 of the 3` UTR sequence, Figure 
5.3B). The position 10381 falls upstream of region A1 of 3`UTR and 
downstream of the stop codon for NS5 (Figure 5.3C). On further investigation, 
the consensus difference was found to reflect a quasi-species frequency 
difference of the G and A variants, found to be 69% and 31% respectively in 
NGC-G, while they were 38% and 62% respectively in NGC-A; indicating a 
shift from G to A in the sequence of NGC-A.  
Apart from this, two low frequency mutations were also found in the open 
reading frame. One of them was at genomic position 1688 which corresponds 
to position 751 in the E region (Figure 5.3B) in NGC-A. There was 1% 
transition from T > G (significant in at least 1% of the population), while the 
reference sequence and NGC-G had the nucleotide T. This means in at least 
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1% of the total viral population, the nucleotide G is present instead of T at 
position 1688 of NGC-A virus, creating a low frequency quasi-species. This 
also changes the amino acid at position 251, where there is a transition from 
Valine (V) to Glycine (G) in the E protein of the quasi-species. Similarly 
another low frequency mutation was found at position 7121 (corresponding to 
position 295 in NS4B, Figure 5.3B) in NGC-G where there was a 3.7% 
transition from A>G, (significant in at least 1% of the population), while the 
reference sequence and NGC-A had the nucleotide A. This again suggests that 
in NGC-G there was a quasi-species representing 3.7% of the population 
which had the nucleotide G instead of A. This changes the amino acid at 
position 99 where there is a transition from Tyrosine (Y) to Cysteine (C) in the 
NS4B protein of the quasi-species. The position 10403 was also found to be 
highly variable in both the strains. The DENV NGCs having the nucleotide G 
and A as consensus at position 10381 are referred as NGC-G and NGC-A 




Figure 5.3 Positions of the mutations found in the NGC-A sequence. (A) Position 
of the mutation at 10381 position in the consensus sequence alignment of NGC-A 
when compared to NGC-G and reference sequences. (B) Position of the mutation in 
the 3` UTR (red star) and the positions of the low frequency mutations found in the E 
and NS4B regions (yellow stars) in the sequence of NGC-A virus. (C) Position of the 
mutation (Black arrow) near the A1 region of 3`UTR and the region (black box) for 
which structure prediction was done). Picture (C) was adapted from (Wilm et al. 
2012) 
5.2.3 The G10381A mutation alters the structure of the virus 
To find out whether the mutation causes changes in RNA structure, the 
structure with the highest stability (free energy) was predicted for the 
sequences of NGC-G and NGC-A spanning the mutation with 10 nucleotides 
upstream of the first stem loop and A1 with 10 nucleotides downstream 
(Figure 5.4A). It was observed that the mutation required higher energy levels 
to maintain its structure, thus making the conserved structure of A1 less stable 
and this was a more significant change in structure than that would be 
expected by chance (Figure 5.4B).  
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Moreover, the base pairing direction had a strong shift at position 10403 due 
to the mutation at 10381 in NGC-A (Figure 5.4C). The nucleotide at the 10381 
position in NGC-G is in the stem loop and the variable nucleotide at 10403 
position is at the 3`end of the terminal loop. In NGC-A however, the 
nucleotide at 10381 position has been shifted 5 base pairs to the base of the 
stem loop while the variable nucleotide at the 10401 position shifted to the 
5`end of the terminal loop. In summary, the overall structure changes and is 
less stable due to the mutation at 10381 in NGC-A. The mutation immediately 
follows the stop codon of NS5 and the position of the nucleotides in the 
terminal loop change. Since the stop codon of NS5 and the terminal loop are 
known to be important for replication, there is a clear effect on the replicating 





Figure 5.4. Structure predictions for DENV 3`UTR A1 region with and without 
mutations. (A) Predicted structures for the region from Figure 5.3 for NGC-G with 
original nucleotide in green (left) and NGC-A (mutant nucleotide in red (right). The 
blue nucleotide shows the varibale region at 10403. (B) The RNA fold mean free 
energy (MFE) distribution of the mutants showing high MFE for the observed mutant 
(C) Base pair prediction for the region from (Figure 5.3) for NGC-G (original 
nucleotide in green; top) and NGC-A (mutant nucleotide in red; bottom). The blue 




5.2.4 Effect of the mutations in vivo 
 To study the effect of the mutations in vivo, 12-15 week old humanized mice 
were infected i.v with 1x10
7
 pfu of NGC-G or NGC-A. The serum was 
analysed for the presence of virus by RNA isolation and qRT-PCR at 7dpi and 
human platelet counts in the blood were taken on before infection, 3 and 7 dpi. 
All humanized mice infected with NGC-G had detectable levels of viremia 
present in the serum while  only 3 out of 5 mice infected with NGC-A had 
detectable levels of viremia in serum on 7dpi. The levels of the other mice fell 
below the PCR sensitivity level of 100 copies (Figure 5.5A). However, both 
the strains caused similar levels of human platelet drop in the infected mice on 
3 and 7 dpi (Figure 5.5B). To see how long the viremia persists, groups of 12-
15 week old humanized mice were infected i.v with 1x10
7
 pfu of NGC-G or 
NGC-A and euthanized on various dpi for analysis. Consistent with the 
previous observation, all the mice infected with NGC-G had detectable 




 copies during the initial 




 copies by 30 dpi (Figure 5.5C). However, 
less than 50% of the mice that were infected with NGC-A had detectable 
viremia in the serum while a significant proportion of them fell below the 
detection level of the qRT-PCR. The peak viremia level in the NGC-A 













Figure 5.5. Effect of the mutation in humanized mice infection. Humanized and 
non-humanized mice were infected with 1x10
7
 pfu of NGC-G or NGC-A virus i.v. 
Mice were sacrificed at the indicated dpi and RNA was isolated from serum. Levels 
of viral RNA were measured by qRT-PCR. (A) Comparison of infection of 
humanized mice with NGC-G and NGC-A on 7dpi. Shown are viral copies per ml of 
serum of humanized mice (5 per group) infected with NGC-G or NGC-A euthanized 
on 7dpi. (B) Similar levels of platelet drop in both the groups. 10l of whole blood of 
the mice were taken before and 3 and 7 dpi, stained with hCD41 and mCD41 and 
counted by flow cytometry using fluorescent beads. The count of human platelets in 
each mouse at various dpi was normalized to the respective counts before infection. 
The averages and SEM are plotted over time. (C&D) Comparison of infection of 
humanized mice with NGC-G and NGC-A for a month. Shown are viral copies per 
ml of serum of humanized mice infected with NGC-G (C) or NGC-A (D) euthanized 
on indicated dpi. (A,C,D) Each symbol represents serum or tissue from one mouse. 
The horizontal lines indicate the average viral copies in each tissue or serum collected 
from mice at the same dpi. The dotted lines indicate the sensitivity of PCR at 100 
copies. The numbers in the parentheses indicate the number of mice where viral 
copies were below the detection limit. 
To determine if the NGC-G virus could replicate in mouse cells, non-
humanized mice were injected with both the viruses and the viral load in the 
serum was analysed on 1,3 and 6 dpi. Interestingly, all the mice injected with 
NGC-G had detectable viremia in the serum while none of the NGC-A 
injected mice showed viremia at all dpi (Figure 5.6). These results suggest that 
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while NGC-G had good replication ability in mouse cells, NGC-A, which 
contains the mutation, could not infect the mouse cells. 
 
Figure 5.6. Effect of the mutation in non-humanized mice infection. NGC-A virus 
does not cause infection of non-humanized NSG mice in comparison with NGC-G. 
Viral copies per ml of serum is shown in both groups (n=3 per group). Each symbol 
represents serum or one tissue from one mouse. The horizontal lines indicate the 
average viral copies in each tissue or serum collected from mice at the same dpi. The 
dotted lines indicate the sensitivity of PCR at 100 copies. The numbers in the 
parentheses indicate the number of mice where viral copies were below the detection 
limit. 
5.2.5 The quasi species with the mutation in NGC-A becomes dominant 
as the infection progresses after undergoing replication in vivo. 
To determine which quasi species had survived and replicated in the infected 





per ml of serum were selected for sequencing. RNA was isolated from the 
serum of two humanized mice infected with NGC-G (from 15 and 30 dpi), two 
humanized mice with NGC-A (from 3 and 7 dpi) and from three non-
humanized mice infected with NGC-G (from 1, 3 and 7 dpi). As the amount of 
cDNA obtained was insufficient to do the whole genome sequencing, only 
certain regions were amplified and sequenced using Illumina NGS approaches 
(Figure 5.7A). The depth of coverage of the sequences from infected 




 reads). Although the viral 
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sequences could be detected in the non-humanized mice, their depth of 
coverage was very low coverage (less than 100 reads) (Figure 5.7 B, C, D).  
 
Figure 5.7.  Coverage plots for the sequences of the viruses isolated from serum 
of NGC-G and NGC-A infected humanized and non-humanized mice during 
NGS. The viral RNA was isolated from the humanized mice infected with NGC-G 
(15 and 30 dpi) and NGC-A (3 and 7 dpi) and non-humanized mice injected with 
NGC-G (1dpi (n=2),3 dpi (n=2), 6 dpi) and sequenced. (A) Regions of the viral 
sequences that were amplified during the sequencing of the samples from the infected 
mice. The number in blue shows the regions amplified (B,C,D) The coverage plots of 
the seqeunces from the serum of the humanized mice infected with NGC-G (B), 
NGC-A (C) and non-humanized mice infected with NGC-G (D). 
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In the humanized mice infected with the NGC-G, the quasi species with the G 
variant had been positively selected after undergoing replication in all the 
mice. This was also observed in the sequences isolated from non-humanized 
mice injected with NGC-G (Figure 5.8). In the humanized mice infected with 
the NGC-A, the quasi species having a G (which was present only in 38% of 
the injected virus) had been selected over the quasi species having a A 
initially. During peak viremia at 7dpi, the A variant resurfaces (as the quasi 
species having the A variant appeared in only 7% of the population on 3dpi in 
the mice but increased to 37% of the quasi species population on 7dpi), but 
was still not high enough in frequencies for selection in consensus sequence. 
However, due to its unstable nature of the A variant, the virus levels slowly 
decrease in these mice and gets cleared from all the mice by 28 dpi, unlike in 
NGC-G infected humanized mice. These data suggest that the quasi species 
having the G could infect mouse cells only when it is present in sufficient 
quantities. In contrast, the quasi species having the A variant is unable to 
infect mouse cells but can infect human cells, however at a much lower 
efficiency than the rate at which the G variant can infect mouse cells. Also, as 






Figure 5.8  Sequence alingment of the isolated RNA sequences. Alignment of 
regions from 10376 to 10404 from the sequences of humanized mice infected with 
NGC-G and -A and from non-humanized mice (NSG) infected with NGC-G, 
compared to the seqeunces of the viruses from mosquito cell culture (NGC-G and 
NGC-A) and reference strain (DENV 2). 
Table 5.1 gives detailed information about the frequencies (in percentage) of 
the nucleotides G and A, at position 10381 of the viruses NGC-G and NGC-A 
when passaged through mosquito cells, humanized mouse and non-humanized 
mouse. 
Table 5.1 Mutations and the frequencies of the quasi species in NGC-G and NGC-A viruses 
Position Nucleotide 
Frequency in 
mosquito cells (%) 
Frequency in 




NGC-G NGC-A NGC-G NGC-A NGC-G NGC-A 
10381 
(3`UTR) 














Frequencies of the quasi species having G or A at 10381 position in the viruses NGC-G and NGC-
A isolated from mosquito cells, humanized mice (one mouse each at 15, 30 dpi for NGC-G and 3, 7 
dpi for NGC-A) and non-humanized mice (one mouse each at 1, 3, 6 dpi for NGC-G) expressed as 
percentages. As NGC-A could not infected non-humanized mouse, there were no DENV sequences 




5.3 DISCUSSION AND CONCLUSION 
In this study two strains of the NGC virus was compared, where a specific G 
to A shift at the 10381 position of the genome, which falls in the 3`UTR was 
identified. This change was associated with replication efficiency changes in 
vitro and may result in a change host tropism of the virus. In particular, it was 
found that the G variant had a higher replication efficiency in mosquito cells 
and a higher affinity to infect mouse cells; while the A variant, with a 
predicted less stable 3`UTR structure, had a lower replication efficiency in 
mosquito cells, no replication ability in mouse cells, but a weak ability to 
infect the human cells of the humanized mice. The reduced replication 
efficiency of the A variant is most likely a result of the mutation altering a 
conserved region of the 3`UTR at its terminal loop of the stem structure. This 
terminal loop is known to be important in the interaction with other proteins 
during replication. Thus this study elucidates that a single nucleotide variation 
in the genome of the virus has the ability to cause a major shift in the host 
tropism of the virus. Through clonal and NGS, it was established that the two 
variants existed as quasi species, with each representing a minority variant in 
the population of viruses when the other formed the majority (consensus) 
sequence. 
Thus, when the mice were infected with either NGC-G or NGC-A, the mouse 
background leads the majority of the sequence to become a G. The detection 
of viral particles even at 7 dpi in the non-humanized mice infected with NGC-
G suggests that the G variant can more efficiently replicate in mouse cells, 
causing selection pressure to favour the G variant. This lead to the 
disappearance of the A variant by 15 dpi and an increase in the level of 
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viremia at later time points in the NGC-G infected humanized mice. Since the 
original NGC was isolated from serial passaging in the mice (Shurtleff et al. 
2001), it is expected that the NGC-G may have been selected to infect mouse 
cells.  In contrast, there was no detectable viremia in the serum of the non-
humanized mice infected with NGC-A virus at all-time points. They had a 
higher level of the A variant, suggesting that the A variant could not infect 
mouse cells. The levels of G variant (present in just 38% of the population 
before injection), were probably insufficient to produce detectable viremia in 
the serum of these mice.  
The longer time taken to form syncytium in the mosquito cell lines infected 
with NGC-A virus (which had the higher levels of the A variant) but not in the 
NGC-G virus, indicates that there might be a correlation between the levels of 
A variant and time taken for the virus to replicate in the cells. When the 
humanized mice are infected with the NGC-A virus both the A and G quasi 
species infects the respective target cells. The predominant A variant however, 
take a longer time to replicate in the infected cells, thus allowing G variant to 
temporarily dominate in the infected humanized mice (as there was 93% of the 
G variant in the sequences isolated from the infected mice). As the infection 
progresses by 7 dpi, the A variant adapts to the human cells and the level in 
the serum increases. This might be due to the A variant being positively 
selected, with the levels of the G variant slowly decreasing. However, as the 
structure of the A variant is less stable, causing reduced replication efficiency; 
it might not be able to sustain more than 28 dpi, which is probably why the 
virus gradually disappears from the infected humanized mice.  
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In summary, it can be concluded that the position 10381 of the NGC sequence 
is important for the structure of the 3`UTR region. The mutations in this 
region can seriously compromise the replication efficiency of the virus. A 
probable explanation for this is that the structural change in 3`UTR might alter 
the circularization between the 3` and 5` UTR and can reduce the interaction 
between them which is important for translation (Sabin and Schlesinger 1945) 
and in turn replication, thus reducing replication efficiency. Alternatively, the 
virus may use the 3`UTR to suppress the host innate immune response such as 
the IFN type 1 for its survival. There is a probability that the 3`UTR, 
specifically the terminal loop, which forms pseudo knots, could play an 
important role in specific host proteins helping in replication or evading 
responses (Blackwell and Brinton 1997;Gomila et al. 2011)Alterations of the 
sequence in the terminal loop might inhibit host-viral interactions and thus can 
change the replicating efficiencies in different host cell types leading to a 
difference in host tropism. More studies could be performed to further 
characterise the mutation at this position and to understand how the single 
nucleotide variations affects the host tropism. Plaque purification and 
amplification of the A and G variants can be performed to determine if there is 
a constant switch between both the variants, which could help to better explain 
the observed results. Another way is to perform a G to A substitution in the 
viral particles to demonstrate the effect of this single nucleotide variation in 

















CHAPTER 6: CONCLUDING REMARKS 













Due to the 65 million years of evolutionary divergence between mouse and 
human, there can be never an ideal mouse model that can entirely mimic all 
the symptoms or characteristics of a disease as it occurs in humans or 
substitute for a human subject or volunteer in clinical trials, before a 
therapeutic is brought into the market. Nevertheless, the search for the 
‘closest’ in vivo model to mimic humans is still being pursued and every 
trickle of knowledge obtained can bring it a step forward. 
Systemic DENV infection was established in the humanized mouse model for 
DENV2 viruses in this study, with some characteristic symptoms of dengue 
infection in humans, such as transient leukopenia and thrombocytopenia. As 
the virus could replicate efficiently only in human cells, it triggered the mature 
human cells to respond to dengue infection. The probable recruitment of 
hCD14
+
 monocytes from BM to blood and the liver damage due to infiltrating 
immune cells are the responses to DENV infection which could be measured 
in the human immune system of the infected mice The humanized mouse 
model for dengue developed in this study has several unique advantages which 
when compared to the previous humanized NSG mouse models for dengue has 
allowed the study of certain aspects of dengue disease. Observing significant 
levels of human platelets and consistently observing thrombocytopenia of 
these human platelets following DENV infection are the salient features that 
have helped in the understanding of the mechanism of thrombocytopenia 
during dengue disease. It was also observed that thrombocytopenia was a 
positive indicator of DENV infection and may be associated with depletion of 
platelet progenitors, human MKs and human MK progenitors, the CFU-MK in 
the BM. Inhibition of MK development in the BM and therefore suppression 
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of platelet production may be the primary cause of thrombocytopenia, as the 
depletion in this model occurred in the absence of peripheral clearance by 
antibody mediated complexes. Thus, these findings and the improved 
humanized mouse model of dengue infection could facilitate the study of 
dengue infection and its pathogenesis in a human cell context.   
6.1 Drawbacks and potential directions to overcome it 
The model described in this thesis characterises the DENV infection in 
humanized NSG mouse. However, there are certain drawbacks in this model 
such as lower levels of viremia and viral load, persistence of viremia due to 
weak antibody response to dengue specific antigens and absence of plasma 
leakage or the manifestation of severe disease. Thus, the model described gere 
could be enhanced so that some of these drawbacks could be overcome, 
resulting in a more robust model. 
i. Low viral load after infection 
The humanized NSG mice after DENV infection develop low levels of 
viremia, because of which assessing viral titres in the mice becomes very 
difficult. Moreover, since there is a correlation between high viral load and 
disease severity (Rakotondrafara et al. 2006), a reason for the low immune 
response seen in these mice could be because of the low viral load. Two 
reasons can attribute to it – characteristic of the dengue viral strain (NGC) or 
low levels of target cells such as monocytes. To overcome the drawback that 
the low viral load could be strain dependent, clinical strains (such DENV2 
07K2861, which showed relatively higher viral load compared to the lab 
adapted NGC) or other serotypes of DENV could be used. However, before 
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other strains are tested, they should first be screened by infecting non-
humanized mice to ensure the viruses are human cell specific and not mouse 
adapted. If the virus can infect only the human cells in the mice, then it makes 
the model more relevant to study the disease pathogenesis in a human cell 
context. Also if possible, the strain should also be screened for a homogenous 
population (and with the least number of quasi-species variants) before using 
it to infect the humanized NSG mice. Further, other infectious doses could 
also be tested systematically to choose the optimal dose of infection.  To 
increase the levels of the target cells, the hCD14
+
 monocytes/ macrophages 
can be boosted through hydrodynamic injections of plasmids containing the 
gene of the cytokine MCSF into the humanized mice (Vaughn et al. 2000). In 
a pilot experiment done, the target cell population was successfully increased 
through this process. However, the treatment resulted in depletion of human 
platelets within a week of boosting the cells. In addition, when infected with 
DENV, viral load could not be detected in any organs, suggesting that 
infection might not have taken place. A possible reason for this could be that 
even though monocytes/ macrophages are targets for dengue infection, they 
are also phagocytic cells, which can clear the infection. Thus a delicate 
balance needs to be maintained between the number of target cells and the 
level of input virus. Thus, boosting hCD14
+
 cells did not lead to an increase in 
viremia in this pilot experiment, probably due to clearance of the virus by the 
increased number of monocytes. Experiments should thus be conducted to test 
this and the quantity of plasmids that are injected, the time of infection and the 
dose of virus should be optimized, such that there are just enough target cells 
for the virus to replicate, but not too much that can clear the infection. The 





monocytes boosted mice can further be investigated, to give new insights into 
the additional factors contributing to thrombocytopenia. Further, NK cells 
could also be specifically boosted or depleted to see if it could alter the level 
of viremia or viral load in the mice as increased levels of NK cells have also 
been associated with mild dengue disease (Chen et al. 2009).  
ii. Poor antibody response and persistence of viremia 
The humanized NSG mouse model for dengue described in this study has 
inherent defects in immune architecture, resulting in poor and intermittent 
production of dengue specific IgM antibody and total absence of dengue 
specific IgG antibody; concurrent with other published models (Azeredo et al. 
2006;Mota and Rico-Hesse 2011). Due to this drawback, the viremia is 
present over extended periods of time in some mice (until 28 dpi) a feature 
that is not seen in patients. Moreover, some potential therapeutics or vaccine 
candidates cannot be tested in the absence of dengue specific humoral 
response. It has been shown that hydrodynamic injections of GM-CSF and IL-
4 into humanized NSG mice helps the B, T and dendritic cells to mature and 
results in an enhanced antigen specific humoral response (Jaiswal et al. 2009). 
This method could be exploited in the humanized NSG mouse model for 
dengue by doing specific hydrodynamic injections of GM-CSF and IL-4 
before dengue infection to allow the production of dengue specific antibodies 
after infection. It might be interesting to see what effects the dengue specific 





iii. Lack of severity and other symptoms 
There is an absence of plasma leakage and haemorrhage, which are 
manifestations of severe disease possibly due to the absence of an interaction 
between human immune modulators and mouse endothelial cells. This might 
be a perennial drawback in the model unless transgenic expression of human 
endothelial cells can be made in these mice. However, symptoms of sickness 
such as hunched posture, ruffled fur or lethargy may be caused when there is 
proper activation of the immune cells through the enhancements mentioned 
above and production of high levels of cytokines (as observed in the 
humanized mouse model for Ebstein-Barr virus infection developed in our lab, 
where there was massive inflammation and production of cytokines in the 
infected mice and correspondingly the mice appeared very sick). Sickness 
might also be DENV strain-dependent, thus using a clinical strain isolated 
from the patient with severe dengue may result in higher activation of immune 
cells and perhaps more severe features of the disease in these mice. 
Thus, the suggested improvements may help in the enhancement of both viral 
load and disease, and helping to make the model more relevant to human 
dengue disease. 
6.2   Utility of the model and future directions  
Despite of the challenges and drawbacks in this model, it can be used 
effectively to study molecular mechanisms of dengue infection and 
pathogenesis in a human cell context, as well as the interactions between the 
host and viruses during infection, which cannot be studied in humans or in 
other mouse models. This model can be used not only to understand aspects of 
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the pathogenesis of dengue disease in a human cell context but also help in the 
study of certain aspects of the virus, which will be explained briefly below.  
i. To understand disease pathogenesis in a human cell context 
The main advantage of the humanized mouse model over other immune-
compromised or competent mouse models is the presence of human immune 
cells and the advantage of the model developed in this study over other 
published humanized NSG mouse models for dengue is the presence of human 
hepatocytes and human platelets. Thus, these features can be exploited to 
understand the dengue disease pathogenesis in a human cell context. A few 
examples are discussed here: 
Thrombocytopenia: In this thesis, the model had been already used to develop 
on the understanding of the mechanism behind thrombocytopenia, one of the 
main characteristic of dengue disease. The DENV infection caused a drop in 
the frequencies of human megakaryocytes in the bone marrow, which 
ultimately may have resulted in a drop in human platelets, while there was no 
change in mouse platelets. While there was little data presented, our working 
hypothesis would be that DENV infection in the BM caused a chemokine/ 
cytokine response that prevented the platelet production. These experiments 
would have been very difficult to perform on other mouse models (due to 
absence of human platelets) and on patients (due to logistic issue of obtaining 
bone marrow samples). Potential future direction for this study would be to 
analyse how the megakaryocytic pathway and the micro environment of the 
bone marrow are disturbed and affected. This can be done by doing a gene 
expression analysis on the human megakaryocytes and other cell types sorted 
from the bone marrow of the infected mice to analyse for apoptotic markers, 
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cytokine profiles and the pathways affected due to dengue infection in the 
bone marrow.  
Role of specific human cells during DENV infection: To study the response 
from individual human cell types such as immune cells or hepatocytes during 
dengue infection, they can be specifically sorted out and a gene expression 
profiling could be done before and after infection in the blood of the same 
infected humanized mice. Changes in the gene expression profiles of these cell 
types can also be done in the various organs (such as human hepatocytes in the 
liver) at different time points throughout the infection. But a challenge in this 
method would be that the infected and uninfected cells would be mixed and it 
might be difficult to study the expression of infected cells specifically. Sorting 
the infected cells by flow cytometric methods might be helpful. The role of 
specific immune cell types in dengue disease pathogenesis can also be studied 
in this mouse model by selectively increasing them through hydrodynamic 
injections of plasmids containing the specific genes (Chen et al. 2012) or or by 
depletion experiments by decreasing their cell populations through injection of 
the respective antibodies and observing the disease outcome and various target 
cell responses through a complete gene profiling of the cells in the blood at 
different time points of the disease. These studies will give a clear insight into 
how the host responds to the infection in a cell specific manner.  
Antibody dependent enhancement: This phenomenon could also be studied in 
the humanized mouse for dengue. In pilot experiments, an attempt was made 
to model ADE in the humanized mice. In the first attempt, the DENV was 
complexed with humanized anti-dengue antibodies (3H5 or 4G2) in vitro, at 
concentrations that proved to enhance the infections in THP-1 cell lines, 
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before injecting them into the humanized mice. However, the viral load could 
not be detected in any of the organs in the infected mice at 3, 5 and 7 dpi, 
suggesting that the virus had been neutralized in the mice. This may suggest 
that neutralization or enhancement may depend on a number of factors such as 
cell maturity etc. To attempt ADE from a different perspective, humanized 
antibodies were injected at various time points such as 1 day before infection 
and 1, 3, 5 dpi, because in humans sub-neutralizing levels of antibodies are 
already present before infection. However, again viral load was not found in 
the organs of the humanized mice. Even though there was thrombocytopenia 
of human platelets, the fold change in reduction in human platelets was similar 
to the control infected group. This suggests that a productive infection had 
taken place but there was no enhancement of disease. Further work can be 
done to model ADE in this humanized mouse by either changing the dose of 
virus or optimizing the concentrations and the time of antibody treatment or by 
injecting antibodies against another serotype before infection with DENV2.  
ii. To understand aspects of DENV host tropism 
Using this model, the factors that could change the replication efficiency or 
the host tropism of the virus can also be analysed. The observation that the 
mutation in the 3`UTR of the DENV has an effect on the replication ability 
and thereby possibly change the host tropism of the virus could be investigated 
further to understand more about the mechanisms behind this. Further work 
can be done by using different clinical strains and assessing the capability to 
infect humanized, non-humanized NSG mouse and the wild type mouse. This 
will give a deeper understanding to why some strains can infect mouse models 
while some do not and the adaptation required for that change. More profound 
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analysis of this kind can also give way in constructing attenuated strains or 
replication defective strains, which could be used as potential vaccine 
candidates. 
6.3 Concluding remarks 
In summary, a humanized mouse model of dengue infection was established 
that recaptures some of the characteristic clinical symptoms including 
transient leukopenia, elevation of blood monocyte levels, thrombocytopenia 
and liver damage. Using this model, the mechanism underlying the depletion 
of human platelets was further investigated, helping to gain insight into an 
important aspect of DENV-induced pathogenesis in a human cell context. The 
model was also used to study the differences in replicating ability of two 
viruses in mouse and human cell types, possibly pointing to a change in the 
host tropism of the virus. Though there are drawbacks, this model can still be 
used in a variety of ways to understand the complex interaction between 
DENV and the host. Overcoming the limitations could make the model even 
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